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Abstract 
 Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3 
botulinum) are attractive therapeutic targets in ovarian cancer based on their 
established importance in tumor cell migration, adhesion and invasion. Despite a 
predicted benefit, targeting GTPases has not yet been translated to clinical 
practice. Based on lead identification through high-throughput screening and 
computational shape homology approaches, R-ketorolac is identified as a Cdc42 
and Rac1 regulator, an activity that is distinct from the anti-inflammatory, 
cyclooxygenase inhibitory activity of S-ketorolac. In this dissertation, R-ketorolac 
is established as an allosteric inhibitor of Cdc42 and Rac1. Studies on 
immortalized human ovarian adenocarcinoma cells (SKOV3ip), and primary, 
patient-derived ovarian cancer cells show R-ketorolac is a robust inhibitor of 
growth factor or serum dependent Cdc42 and Rac1 and their downstream 
effector p21-activated kinases activation. Multiple assays of cell behavior show 
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that R-ketorolac significantly inhibits cell adhesion, migration and invasion. A 
clinical trial on ovarian cancer patients shows that ketorolac is enriched in the R-
enantiomer in peritoneal fluids and GTPase activity is inhibited in ascites-derived 
tumor cells. A retrospective study suggests that a single dose of ketorolac in the 
perioperative period benefits patient outcomes. In sum, R-ketorolac inhibits 
Cdc42 and Rac1 activities and subsequent physiological consequences which 
are critical to tumor metastasis and likely contributes to the observed survival 
benefit in ovarian patients.  
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CHAPTER 1 
INTRODUCTION 
Ovarian Cancer 
Ovarian cancer is the fifth leading cause of gynecological cancer deaths in 
the United States with a 45% 5-year survival rate (1). A majority of malignant 
ovarian cancer in adult women is epithelial ovarian cancer, which is classified 
into distinct morphologic categories, including serous, mucinous, endometrioid, 
clear cell, transitional cell, or any combination of these (2, 3). Recent 
understanding of the etiology of “ovarian cancer” suggests that it is a general 
term for a series of molecularly and etiologically distinct diseases that simply 
share an anatomical location. New evidence shows that a majority of serous 
ovarian cancers originate from the distal end of dysplastic fallopian tubes, mostly 
presenting at an advanced stage disease; whereas early stage carcinomas, 
including clear-cell carcinoma, endometrioid, and low-grade serous carcinoma 
usually derive from endometriosis or borderline serous tumors (4-7). 
Serous ovarian carcinoma is the most common (~70%) and aggressive 
epithelial ovarian tumor that is usually diagnosed at advanced stages with a high 
relapse rate (8). Due to lack of symptoms and effective early predictive markers, 
most patients are diagnosed at late stages with tumor dissemination on multiple 
abdominal organs at laparotomy (9, 10). A majority of patients relapse although 
tumor cannot be detected after first-line surgery and chemotherapy. Another 
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difficulty for ovarian cancer treatment is tumor heterogeneity. Many ovarian 
cancers are derived from non-ovarian tissues and share few molecular 
similarities among different histotypes (4-7). This leads to failure of most 
molecularly targeted therapies that are only effective at some tumor sites, and 
explains the high recurrence rate of a tumor that responds to initial treatment but 
soon develops chemoresistance (11-13). Thus, in comparison to other epithelial 
malignancies, the survival rate of epithelial ovarian cancer has shown little 
improvement since precise surgery and target chemotherapy were introduced 
over the past 30 years (14-16). 
Ovarian Cancer Metastasis and Microenvironment 
Often associated with malignant ascites, which facilitates metastasis, most 
patients are diagnosed at advanced stages with dissemination throughout the 
intraperitoneal cavity (17). Unlike many other epithelial cancers, at early stages, 
epithelial ovarian tumors grow and extend to the proximal sites adjacent to the 
primary tumors by cell proliferation, migration and colonization (16, 18). 
Metastatic spread of ovarian cancer beyond the ovary or fallopian tube is 
mediated by disruption of the ovarian tumor capsules and surface shedding of 
malignant cells from primary tumors into the peritoneum, where tumor cells 
survive as free-floating multicellular aggregates (MCA) in the ascites fluid, 
commonly known as spheriods. Subsequently, MCA anchor and attach on 
mesothelial extracellular matrix (ECM) and invade into the submesothelial matrix, 
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which leads to secondary lesions on peritoneal organs and surfaces at later 
stages (19, 20) (Figure 1). 
Recent studies have shown that the tumor microenvironment contributes to 
the late diagnosis, intraperitoneal dissemination, chemoresistance and frequent 
recurrence (21, 22). The tumor microenvironment has a multicellular composition 
that includes tumor cells, tumor-infiltrating immune cells and stromal cells with 
the peritoneal cavity being considered as a highly receptive environment for 
carcinomatosis (22, 23). Mesothelial cells form a protective monolayer that 
maintains normal serosal membrane integrity and function. Peritoneal 
mesothelial cells play pivotal roles in protecting organs from tumor dissemination 
(24, 25). However, malignant tumor cells anchor on the mesothelium by 
overexpressing CA125 which facilitates cell implantation via the interaction with 
mesothelin expressed on mesothelial cells, and further invade into the 
submesothelial ECM of organs by secreting surface matrix metalloproteases 
(MMP) (26). The CD44/hyaluronan/vercican macromolecular complex promotes 
tumor cell adhesion on mesothelium and invasion into the ECM (27). Integrins 
are involved in cell-ECM and cell-cell interaction, and ascites-associated MCA 
formation that are important for tumor migration and invasion (28, 29). 
Endothelial cells are critical during tumor progression for tumor growth because 
of their functions in neovasculature formation regulated by pro- and anti-
angiogenic factors (30). Adipocytes have been reported to promote homing and 
proliferation of ovarian cancer to the omentum by secreting specific cytokines 
(e.g. IL-6, IL-8), chemokines and lipids (31, 32). Immune cells (e.g. macrophages, 
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T cells, dendritic cells and B cells) are another key component of tumor 
microenvironment because the quality of endogenous immune responses can 
have a significant impact on patient outcomes and are usually suppressed in the 
tumor microenvironment (33, 34). Cancer associated fibroblasts are a major 
component of tumor stroma that facilitate tumor cell growth and metastasis by 
expressing mitogenic factors. Moreover, the tumor stromal fibroblasts are 
speculated to be derived from ovarian surface epithelium that undergo epithelia-
to-mesenchymal transition (EMT) (19, 35). In sum, all these components and the 
communication between them characterize the unique microenvironment that 
regulates ovarian tumor growth, angiogenesis and dissemination.   
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Figure 1.  Model of ovarian cancer metastasis.  At the earliest stage, the 
tumor is limited to one or two ovaries; no tumor is present on the ovarian surface 
or in ascites. Once the tumor progresses to later stages - when most patients are 
diagnosed – it spreads beyond the confines of the ovaries, extends and invades 
to adjacent tissues, such as the uterus, fallopian tubes, and mesothelial lining of 
peritoneum. Metastatic spread of the ovarian cancer beyond the ovary or 
fallopian tube is mediated by surface shedding of tumor cells and formation of 
free-floating multicellular aggregates in the ascites fluid. Subsequent mesothelial 
anchoring and invasion of the submesothelial matrix lead to secondary lesions on 
peritoneal organs and surfaces. (H. Naora, D. Montell, Nature Reviews Cancer, 
2005;5:355-66)  
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Overview of Ovarian Cancer Treatment 
The first line treatment for epithelial ovarian cancer is major debulking 
surgery to remove as much tumor burden as possible, most often followed by 
intraperitoneal chemotherapeutic treatment in optimally debulked patients after 
recovery from surgery (36). Cytoreductive surgery is initially conducted on 
patients with suspected epithelial ovarian cancer to determine a pathological 
diagnosis, precisely evaluate disease stage, and optimally excise tumors when 
feasible (37-39). After a perioperative period that allows patients to recover from 
primary surgery, patients are standardly treated with platinum/taxane based 
cytotoxic chemotherapy (40). The chemotherapeutic drugs are given systemically 
by intravenous (IV) injection, intraperitoneal (IP) injection or mouth, which allows 
the drugs to reach all areas of the body through the circulatory system. Because 
ovarian cancer mostly disseminates within the peritoneal cavity, IP chemotherapy 
is widely used and involves injecting drugs through a catheter directly into the 
abdominal cavity (41). Compared to IV chemotherapy, IP chemotherapy results 
in higher local concentrations of drugs in the peritoneal cavity and results in two-
fold higher drug penetration into tumors (42). Although nearly 75% of patients 
initially respond favorably to chemotherapy, a majority of patients subsequently 
become chemoresistant, develop largely incurable recurrent disease, and die 
within five years (16).  
The perioperative period, which is a days-to-weeks period between 
cytoreductive surgery and the first chemotherapy, has been reported to be crucial 
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for tumor recurrence and metastasis (43). Although the primary tumor is removed 
by surgery along with all tumors > 1 mm, due to wide dissemination and 
microscopic implants throughout the peritoneum, residual malignant tumor cells 
may be present in the circulatory system, distal organs or bone marrow which 
leads to disease recurrence (44, 45). During this period, surgery-induced 
perturbations (e.g. stress, nutritional status, inflammation and anesthesia) and 
consequent paracrine, neuroendocrine and immune responses, including 
increased prostaglandins, growth factors and cytokines (e.g. Tumor necrosis 
factors (TNF), interleukin factor (IL) 6, IL8) and decreased antiantiogenic factors 
(e.g. endostatin), create a pro-metastatic microenvironment, facilitating residual 
malignant tumor cell growth, proliferation, and survival (46-50). The malignant 
tumor cells are either cancer stem cells or metastatic tumor cells, which are 
frequently chemoresistant and represent the major cause of ovarian cancer 
relapse and mortality (51, 52). Therefore, targeting tumor cell adhesion, migration 
and invasion in the perioperative period presents an important potential window 
of opportunity for treatment that has not yet been extensively explored (43, 53).  
Rho GTPases  
  Ras homology guanosine triphosphatases (Rho GTPases) (~21 kDa) are 
a family of small signaling G proteins, which were began to be discovered from  
1985 as Ras-related proteins (54, 55). To date, there are twenty-two mammalian 
genes encoding Rho proteins that have been identified. Cdc42, Rac1 and Ras 
homolog gene family, member A (Rho A) are three well characterized members 
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of the Rho family GTPases (54, 56). Similar to other regulatory GTPases, Rho 
GTPases act as molecular switches by interconverting between an active GTP-
bound form and an inactive GDP-bound form. Because GDP is tightly bound and 
GTP is hydrolyzed very slowly, the cycling between an active and an inactive 
conformational state is regulated by three classes of GTPase regulatory proteins: 
a) guanine nucleotide exchange factors (GEFs), which facilitate GDP dissociation; 
b) GTPase-activating proteins (GAPs), which stimulate GTP hydrolysis; c) 
guanine nucleotide exchange inhibitors (GDIs), which sequester GTPases from 
nucleotide exchange by shielding the lipids that are critical for membrane 
recruitment (54, 56-58) (Figure 2).   
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Figure 2. Rho GTPase activation cycle and roles in signaling pathways. In 
response to stimulatory signals, activated GEFs catalyze the exchange of GDP 
to GTP on Rho family GTPases. Active GTP-bound Rho GTPases interact with 
effector molecules (e.g. PAKs), leading to the activation of signaling cascades 
regulating a variety of cellular processes. GAP proteins promote GTP hydrolysis 
and inactivation of Rho GTPases. Rho GTPase activity is further inhibited by 
GDIs, which sequester the GTPase in the cytosol away from cell membranes.  
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Rho GTPase Signaling Pathways and Their Functions 
 Various extracellular stimuli trigger the activation of Rho GTPases at 
different points (Figure 3), such as G protein-coupled receptors, tyrosine kinase 
receptors and integrin. The seven-transmembrane-domain heterotrimeric G 
protein-coupled receptor family (e.g. bradykinin, Lysophosphatidic acid (LPA) 
and bombesin receptors) activate select Rho GTPases by the activation of 
heterotrimeric G proteins, which subsequently stimulates the RhoGEFs (59). 
Epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and 
insulin-like growth factor (IGF) stimulate the activation of Rho GTPase by 
increasing GEF activity in a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) 
dependent manner. In addition, Rho GTPases are activated by cell-ECM 
adhesion which is mediated by integrins. The cytoplasmic tail of integrin (β1, β3, 
β5) activates focal adhesion kinase (FAK), leading to the phosphorylation of 
downstream protein p130cas that activates DOCK180 (a Rac GEF) and inhibits 
RhoA. Overall, the activation of cell receptors and other molecules influence 
intracellular signaling by regulating Rho GTPase activity (60, 61).  
Cdc42 and Rac1 activate multiple downstream effectors and initiate the 
sequential events which modulate various cell behaviors (Figure 3) (62). For 
example, p21-activated kinases (PAKs) interact with Cdc42 and Rac1 through a 
p21 binding domain (PBD), which causes auto-phosphorylation and 
conformational changes and initiates multiple cellular processes, including F-
actin polymerization, Mitogen-activated protein kinases (MAPK) signaling, and 
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apoptosis signaling (63, 64). Other effectors of Cdc42 and Rac1 include the 
Wiskott-Aldrich syndrome protein (WASP)/WASP-family verprolin-homologous 
protein (WAVE) family and Ras GTPase-activating-like protein (IQGAP), which 
regulate actin nucleation through the actin related protein (Arp) 2/3 complex for 
actin polymerization (65, 66). In addition, Cdc42 promotes cell division and cell 
transformation by inducing the accumulation of EGFR, and facilitating the nuclear 
translocation of EGFR which induces EMT and angiogenesis (67). All these 
processes are critical for the regulation of cell growth, proliferation, motility and 
apoptosis.  
Since Cdc42 and Rac1 GTPases play important roles in actin 
reorganization, their regulators and effectors have been suggested to control 
tumor progression and metastasis (68). The direct effectors of Cdc42 and Rac1 – 
PAK1 and PAK4 – are up-regulated in breast cancer and required for actin 
cytoskeleton remodeling and tumor cell motility (69). In colorectal cancer cells, 
active Cdc42 greatly promotes cells to spread, migrate, and invade via the PAK1-
myosin light-chain kinase (MLCK) pathway important for tumor metastasis (70). 
In breast cancer cells, Rac1 is up-regulated as a consequence of enhanced 
upstream signals from multiple pathways (e.g. phosphoinositide-3-kinase (PI3K) 
and tyrosine kinase receptors (TKR) such as ErbB1/ epidermal growth factor 
receptor (EGFR) in response to EGF or transforming growth factor (TGF) 
ligands), which promotes tumor cell growth and proliferation (71, 72). Activated 
Cdc42 and Rac1 decrease p53 protein levels leading to increased vascular 
endothelial growth factor (VEGF) expression and tumor angiogenesis (73). α6β4 
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integrin-dependent Rac-PAK1 signaling enhances apoptosis-resistance by 
overexpressing nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) protein in mammary acini (74). Rho GTPases stimulate cell cycle 
progression by inhibiting retinoblastoma protein (pRb) checkpoint and reduce 
epithelial cell polarity by down-regulating E-cadherin expression in various 
carcinoma cells (75). In summary, Cdc42 and Rac1 regulate multiple cell 
functions that could affect tumor progression and metastasis.  
Moreover, Cdc42 and Rac1 are frequently overexpressed or 
hyperactivated in epithelial cancers including ovarian cancer. 
Immunohistochemistry studies show that patients with a high clinical stage 
hepatocellular carcinoma (III-IV) had a higher tendency to express Rac1 which is 
associated with shorter disease-free survival, compared to patients with low 
pathologic grade hepatocellular carcinoma (76). Rac1 expression promotes EMT 
and the overexpression correlated with advanced stage  of disease and early 
tumor recurrence in epithelial ovarian cancer patient (77). Rac1b is a Rac1 splice 
variant that adds 19 amino acids and causes hyperactivity through GEF-
independent activation (78-80). Rac1b is overexpressed in breast, colorectal and 
lung cancer, and constitutes a marker of poor prognosis in KRAS/BRAF WT 
metastatic colorectal patients (81-85). Previous work by our group found that 
both Cdc42 and Rac1 were overexpressed or hyperactivated in advanced stages 
of ovarian cancer patients compared to benign or low grade tumor (86). Thus, 
Cdc42 and Rac1 GTPases could be potential pharmacologic targets for the 
treatment of ovarian and other epithelial cancers.  
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In addition to the described canonical Rho GTPases - Cdc42 and Rac1, 
other Rho GTPase isomers also play critical roles in cell proliferation, 
differentiation and cell migration (87). RhoA, -B and -C directly activate actin 
polymerization in stress fiber formation by interacting with ROCK-
LIMP/actomyosin pathways. RhoA and RhoC have been found to promote 
cancer progress, whereas RhoB acts as a cancer suppressor with its 
antiproliferation and proapoptosis effects (88). A similar anti-tumor effect is also 
observed for RhoE targeted by p53 (89). RhoG regulates membrane dynamics 
involved in cell migration and spreading and microtubule dynamics critical for 
platelet granule secretion (90). RhoJ modulates the formation of focal adhesion 
and early endocytosis for endothelial chemotaxis, migration, proliferation and 
lumen formation, which is responsible for the angiogenesis (91).  
Cancer growth and metastasis are directly correlated with the 
misregulation of Rho family GTPases that generally result in  overexpression of 
Rho GTPases and aberrant activity of Rho GTPase regulators (e.g. GEF, GAP, 
GDI). Recently, mutationally active Rho GTPases have been identified using 
high-throughput exome sequencing techniques (92, 93). In about 5-10% 
melanoma, Rac1 (P29S) and Rac2 (P29L) mutants are found to activate the 
GTPases by enabling GEF-independent conversion to the GTP-bound form (93-
95). In C. elegans, MIG-2 (S75F), which might be functionally equivalent to RhoG, 
and CED-10, which might be functionally equivalent to Cdc42, have been 
identified as gain-of –function mutations (96).   
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Figure 3. Cdc42 and Rac1 GTPases regulate multiple downstream signaling 
pathways. Cdc42 and Rac1 promote cytoskeleton reorganization through 
regulation of multiple effectors (e.g. N-WASP/WAVE, IQGAP, PAK) and 
associated subsequent signaling proteins (LIMK, Arp2/3), which are pivotal for 
cell adhesion, migration and invasion. Cdc42 and Rac1 also mediate the 
activation of MAPK signaling pathway through PAK, regulating cell growth, 
apoptosis and proliferation.  
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Rho GTPase Inhibitors 
Since Cdc42 and Rac1 are potential high value therapeutic targets in 
ovarian and other cancers, numerous inhibitors targeting the Rho GTPases have 
been developed. Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors that indirectly act as broad spectrum GTPase inhibitors by 
interfering with the prenylation required for membrane association and have been 
successfully used for the treatment of hypercholesterolemia (97). In recent years, 
statins have been found to induce apoptosis and inhibit proliferation in several 
cancer cell lines. Cancer risk reduction associated with statins use are reported 
for prostate, breast, colorectal, and pancreatic cancers in patients (98-101). The 
benefit in ovarian cancer is mixed and subtype specific (102), motivating the 
identification and testing of more selective GTPase inhibitors. Secramine inhibits 
Cdc42 binding to membranes in a RhoGDI-dependent manner, prevents 
membrane associated Cdc42 activation, and subsequently inhibits the formation 
of actin cytoskeleton mediated platelet integrin α2β1 (103). CID2950007, an 
allosteric inhibitor of Cdc42 nucleotide binding, inhibits Cdc42-related filopodia 
formation and cell migration in cell based assays (104). NSC23766 was 
discovered as a Rac inhibitor and selectively inhibits the interaction between Dbl 
(a Rac GEF) and Rac (105). The compound has been shown to inhibit cell 
growth, proliferation and invasion in prostate cancer and hematopoietic stem 
cells (105, 106). Novel compounds (e.g. AZA1, AZA197, EHop-016) based on 
structural information of NSC23766 have been synthesized and act as Cdc42 or 
Rac1 inhibitors to reduce cell migration and proliferation and tumorigenicity in a 
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xenograft mouse model in prostate and colorectal cancers (107-110). Although 
all these Rho GTPase inhibitors were designed and discovered with various 
modes of action and are predicted to be of great therapeutic benefit, the limitation 
of the Rho GTPase inhibitors lies in their poor selectivity between cancerous and 
normal cells. Therefore, these identified compounds may not be 
pharmacologically suitable for human use and none have as yet been translated 
to clinical application.  
NSAIDs and Their Roles in Cancer Therapy 
Non-steroidal anti-inflammatory drugs (NSAIDs) are potent 
cyclooxygenase (COX) inhibitors that cause reduced synthesis of prostaglandins 
from arachidonic acid. Many of the NSAIDs are marketed as racemates, 
composed of 1:1 mixtures of R and S-enantiomers. The two enantiomers often 
exhibit remarkable pharmacologic and toxicologic differences. The S-enantiomer 
has been shown to preferentially interact with COX (111) and is generally 
considered the active component in racemic drug formulations.  
Recently, besides their analgesic function, several NSAIDs have been 
reported to have significant benefit for patient survival in various cancers. 
Growing evidence suggests that NSAIDs have a variety of molecular targets and 
may contribute to cancer prevention in both COX-dependent and COX-
independent manners. For example, aspirin has been reported to reduce colon 
cancer risk by inhibiting the upregulated expression of COX-2, which promotes 
tumorigenesis in 40-45% of colon cancer (112). The evidence for COX-
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independent pathways is that COX-2 negative epithelial cells exhibit similar IC50 
values as COX-2 positive counterparts in terms of cell growth inhibition with 
celecoxib treatment (113). Furthermore, R-ibuprofen, which does not have COX 
inhibitory activity, is equally potent as the COX inhibitory S-ibuprofen in inhibiting 
PDGF-induced mitogenesis in colon cancer cells and colon cancer development 
in an animal model (114, 115). Numerous targets, in addition to COX, have been 
identified as potential mediators responsible for the chemopreventive action of 
NSAIDs, e.g. inhibition of IκB kinase (IKK)β/NF-κB mediated transcriptional 
activation and cell survival, reduction of protein kinase G (PKG) mediated 
angiogenesis, and downregulation of matrix metalloproteinase (MMP)2 and 
MMP9 mediated invasion (116-120). Although multiple targets have been 
identified for the anti-tumor effect of NSAIDs, there is no evidence of these 
potential targets being directly related to the clincially observed benefits on 
cancer patient outcomes.  
Rationale of the Study 
Using findings obtained from a high throughput screen of the 2007 
Prestwick Chemical Library® (2007) of 100% off patent drugs contained 888 small 
molecules (Prestwick, Washington DC, USA) and cheminformatics approaches, 
the R-enantiomers of a limited number of NSAIDs, R-ketorolac and R-naproxen 
were identified as inhibitors of Cdc42 and Rac1 (121). Ketorolac is an FDA 
approved drug that is administrated as a racemic mixture for post-surgery pain 
management. S-ketorolac inhibits COX-1 and COX-2 enzymes, whereas R-
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ketorolac shows >100-fold less activity on both COX-1 and COX-2 (122). S-
naproxen, but not R-naproxen is an FDA approved drug having analgesic, anti-
inflammatory, and antipyretic activity. Such activity is also mediated via inhibition 
of the COX enzymes (123, 124).  
The central goal of this study is to confirm and characterize the R-
enantiomers of selected NSAIDs, ketorolac and naproxen, as bona fide Cdc42 
and Rac1 GTPase inhibitors and establish their anti-tumor impacts in ovarian 
tumor cells and ovarian cancer patients. R-ketorolac, as a FDA-approved drug in 
racemic form, has potential to be repurposed as an anti-tumor drug for ovarian 
cancer therapy. Chapter 2 identifies the mechanism of R-ketorolac and R-
naproxen on Cdc42 and Rac1 nucleotide binding using a flow cytometry based in 
vitro nucleotide binding assay. Chapter 3 utilizes cell-based assays to 
characterize the inhibitory effect of R-ketorolac on cell adhesion, migration and 
invasion using immortalized ovarian cancer cell lines and primary human ovarian 
cancer cells. Chapter 4 utilizes a clinical trial to establish a novel pharmacologic 
activity of ketorolac for therapeutic benefit in ovarian cancer patients. 
Hypothesis 
R-ketorolac inhibits Cdc42 and Rac1 GTPase activities and associated 
downstream cascades that are central to cell adhesion, migration and invasion, 
which will have beneficial effect in reducing ovarian tumor metastasis and 
progression. 
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Significance and Innovation 
Compared to traditional drug development pipeline requirements, the 
overall time and cost of repurposing R-ketorolac will be greatly reduced because 
of the significant number of toxicology and safety assessments that have already 
been completed. The mechanistic study of signaling pathways inhibited by 
ketorolac will demonstrate Cdc42 and Rac1 as potential therapeutic targets for 
ovarian and other epithelial cancers therapies. Biochemical and structural studies 
of the mechanism of GTPase activity inhibition by selected NSAIDs will provide 
guidance for the development of new anti-tumor chemical entities.  
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CHAPTER 2 
R-KETOROLAC INHIBITION OF CDC42 AND RAC1 NUCLEOTIDE 
BINDING 
Abstract 
Cdc42 and Rac1 GTPases are key regulators of actin reorganization, cell 
motility, cell-cell and cell-extracellular matrix (ECM) adhesion, whose activities 
are found closely correlated with tumor expansion and malignant progression. 
Despite a predicted benefit, targeting Cdc42 and Rac1 GTPases has not yet 
been translated to clinical practice. Through high throughput screening and 
computational shape homology approaches, we established the R-enantiomers 
of selected NSAIDs (ketorolac and naproxen) as Cdc42 and Rac1 inhibitors; 
distinct from the anti-inflammatory, cyclooxygenase inhibitory activity of S-
enantiomer. In this chapter, a bead-based flow cytometry assay was used to 
establish that R-ketorolac and R-naproxen act as allosteric regulators of GTPase 
nucleotide binding by Cdc42 and Rac1. Molecular docking analyses are 
predicated on in vitro nucleotide binding assay results and GEF mediated 
nucleotide exchange mechanisms. R-enantiomers are suggested to preferentially 
interact with magnesium and exclude interaction with the guanine nucleotide 
phosphate residue. A preliminary structure-activity relationship study of ketorolac 
demonstrates that substituents on the phenyl ring are critical in modulating 
ketorolac inhibition of nucleotide binding by the GTPase, offering guidance for 
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generating more selective chemical entities. Taken together, the studies in 
Chapter 2 demonstrate that the R-enantiomers of selected NSAIDs (ketorolac 
and naproxen) act as Cdc42 and Rac1 inhibitors, which may have potential 
benefits for cancer therapy.  
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Introduction 
 The Rho-family (Ras homolog) GTPases are central to dynamic actin 
cytoskeleton assembly and rearrangement that are the underpinnings of normal 
cell-cell adhesion, cell migration and even transformation (54, 125). Among the 
Rho-family GTPases, Cdc42 and Rac1 are of particular interest due to their 
frequent overexpression or hyperactivation in epithelial cancers including ovarian 
cancer (73, 77, 86, 126, 127).  
The conformational GTPase switch is regulated by the bound nucleotide 
(GTP or GDP) and determines the GTPase activation status. The conserved 
domain of Rho GTPases consists of a six-stranded β-sheet surrounded by five α-
helices, known as the switch 1 and switch 2 regions (Figure 4) (58, 128). This 
domain includes the guanine nucleotide binding site that recognizes the guanine 
base as well as the β-phosphate and the Mg2+. This domain is involved in the 
coordination of the β-phosphate and hydrolysis of GTP. For example, in Cdc42 
nucleotide exchange (Figure 5), which is mediated by DOCK9 (a GEF for Cdc42), 
the nucleotide-binding site is first exposed via a conformational transition of 
switch 1. The movement of switch 1 triggered by DOCK9 (for Cdc42) and 
DOCK2 (for Rac1) GEFs facilitates release of GDP via rotation of P-loop Cys18C 
and disrupts interaction with GDP by excluding Mg2+ (129, 130). Mg2+ is regarded 
as enhancing nucleotide affinity by neutralizing the negatively charged phosphate 
groups (128). During GTP hydrolysis, crystal structure analyses showed that 
Rich - a Rho GAP, hydrolyzes GTP by interacting with Cdc42 through the switch 
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1 and switch 2 regions. Specifically, Arg85 of Rho GAP contacts the β-γ oxygens 
and catalyzes the GTP hydrolysis by interacting with P-loop (131, 132). 
Since Cdc42 and Rac1 are potential high value, therapeutic targets in 
ovarian and other cancers, several GTPase targeted inhibitors have been 
identified with various modes of action. Irrespective of whether they affect 
GTPase membrane association by inhibiting protein prenylation (e.g. statins), 
GTPase regulator activity (e.g. NSC23766, secramine) or nucleotide binding 
ability (e.g. CID2950007), none have as yet been translated to human use (99, 
103-105).  
To investigate small molecules targeting Cdc42 and Rac1 which could be 
rapidly translated to clinical application, high-throughput screening and 
computational simulation of the 2007 Prestwick Chemical Library® of off-patent 
and FDA approved drug-like small molecules were conducted and identified R-
enantiomers of selected NSAIDs, R-naproxen and R-ketorolac, as potential 
Cdc42 and Rac1 inhibitors; while S-enantiomers, which are identified as COX 
inhibitors, displayed little or no activity against GTPases.  
In this chapter, a flow cytometry based in vitro nucleotide binding assay 
was used to establish the mechanism of inhibition of the R-enantiomer of 
selected NSAIDs on Cdc42 and Rac1. This approach enables distinction of 
allosteric or competitive inhibition of nucleotide binding.   
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Figure 4. Structure of Rho GTPase. α-helix, β-sheet, switch 1, switch 2, and 
magnesium are indicated. (Vetter, IR et al., Science, 2001,294;1299-1304)  
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Figure 5. DOCK9 mediates the conformational changes in Cdc42 to 
facilitate nucleotide exchange. Cdc42 is colored orange/gold with switch 1(red) 
and 2 (magenta) and P loop (blue). DOCK9 is colored in light blue/purple. GTP 
and magnesium are colored in green. DOCK9 interacts with Cdc42 and triggers 
the conformational change of switch 1, which facilitates Mg2+ exclusion and 
nucleotide exchange of GDP for GTP.  The conformational change of DOCK9 
includes α6 and α10C helices (indicated by arrows) and β3/β4 and β5/β6 loops. 
(Kulkarni, K. et al., The Journal of Biological Chemistry, 2011; 286:25341-51)  
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Materials and Methods 
Reagents 
Superdex peptide beads (13 µm with an exclusion limit of 7kDa) were from 
Amersham Biosciences (custom-order). GST (glutathione S-transferase)-tagged 
GTPases (Cdc42/Rac1) were purified as described previously (133). Compounds 
for dose response assays were obtained as follows: R-ketorolac (K235600, 
Toronto Research Chemical Inc), S-ketorolac (K235605, Toronto Research 
Chemical Inc), R-naproxen (Acme Bioscience #A5026, Palo Alto, CA), S-
naproxen sodium (N5160, Sigma-Aldrich), 6-methoxy-2-napthalene acetic acid 
(6-MNA) (70620, Cayman Chemical, Ann Arbor, MI, USA), NSC23766 (204823, 
Santa Cruz, CA), CID2950007 (71203-35-5, Tocris). GST-PAK1 protein was from 
Millipore (14-864). BODIPY-GTP ((4,4-difluoro-4-bora-3a,4a-diaza-s-indacene or 
dipyrromethene boron difluoride) nucleotide analogue) was from Invitrogen 
Molecular Probes (Cat #: G22360). Ketorolac analogs (Screening Center Vial 
Barcode Number: SKCM101436, 101439, 100846, 104309, 104402, 104352, 
100538, 100897, 102026, 100621, 101671, 103977, 103793, 103959) were 
synthesized by Dr. Jennifer Golden (Associate Director Medicinal Chemistry 
Center, Pharmaceutical Sciences Division, University of Wisconsin). CID2950007 
analogs (44216842-CCCH2CH2NGtBoc(RS-II-16P), 44216842-Iodide(AG-II-106), 
44216842-CCCH2CH2NH2(RS-II-24C), 44216842-Heptynoic-Dioxy-HPY(490)) 
were synthesized by Dr. Jeffery Arterburn (Department of Chemistry, New 
Mexico State University). All compounds were dissolved in dimethyl sulfoxide 
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(DMSO) at 100 mM stock concentrations. Stocks should be aliquoted and 
multiple freeze-thaw cycles avoided.   
Expression and Purification of GST-Cdc42/Rac1 
GST-Cdc42/Rac1 protein was expressed in E. coli BL21 (DE3). Cultures 
were grown at 37ºC to a bacterial density of 0.6-0.8 absorbance units at λ=595 
nm. Bacteria were chilled on ice for 20 min and then induced by transfer to room 
temperature and addition of 0.2 mM isopropyl-beta-D-1-thiogalactopyrano- side 
(IPTG) for 16-18 h to maximize yield of properly folded active fusion protein. 
Purification of GST-Cdc42/Rac1 was used for the flow cytometry based in vitro 
nucleotide binding assay according to standard procedures (133).  
Synthesis of Glutathione (GSH) Beads for Flow Cytometry Assay 
High density glutathione (GSH) conjugated beads were synthesized for flow 
cytometry assays by loading Superdex peptide beads with GSH as previously 
reported (134). Typical site occupancies of the beads at saturation are in the 
range of 1 to 4 ×106 ligand sites/bead (determined by the characteristic kinetic 
and equilibrium binding of GST fused green fluorescent protein (GFP) (135). 
Immobilization of Cdc42/Rac1 on GSH Beads for Flow Cytometry 
All in vitro nucleotide binding to GTPases and measurements were 
performed in HPS buffer (30 mM Hepes, pH 7.5, 20 mM NaCl and 100 mM KCl) 
containing 1 mM EDTA, 0.1% BSA (w/v) and 0.01% NP40 (v/v). A Becton 
Dickinson FACScan flow cytometer with a 488 nm excitation laser and standard 
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detection optics was used for all assays (133). Purified GST-tagged Cdc42/Rac1 
protein was incubated in a 1.5 ml Eppendorf tube at 4ºC overnight with 2×105 
GSH beads in a total volume of 100 µl of HPS buffer containing 1 mM EDTA, 1 
mM dithiothreitol (DTT) added fresh and 0.1% BSA (w/v). Unbound protein was 
removed by centrifugation and washes by spinning GTPase bound beads twice 
at 800 g followed by resuspension of washed beads in fresh HPS buffer with 1 
mM EDTA, 1 mM DTT added fresh and 0.1% BSA (w/v).  
Flow Cytometric BODIPY-GTP Binding Assay 
The nucleotide binding assays were carried out according to the protocols 
described previously (134). In order to measure BODIPY-GTP binding to Cdc42 
and Rac1 GTPases, the in vitro nucleotide binding assay was performed in HPS 
buffer containing 1 mM EDTA in order to chelate the magnesium and facilitate 
GTPase nucleotide exchange. Briefly, individual GST-GTPases were allowed to 
bind to their respective GSH beads and combined. In the equilibrium assay, 2 
×103 GSH beads loaded with GST-GTPase were pre-incubated with either 
DMSO or a fixed compound concentration for 15 min followed by incubation with 
varying concentrations of BODIPY-GTP for 30 min at room temperature. A stock 
solution of ketorolac was prepared by dissolving to 10 mM concentration in 
DMSO. A three-fold serial dilution was made from the 10 mM stock in DMSO. In 
dose-response assays, 2 ×103 GSH beads loaded with GST-GTPase were pre-
incubated with DMSO or increasing concentrations of the compounds for 15 min 
followed by incubation with a fixed concentration of BODIPY-GTP for 30 min at 
room temperature. Final DMSO concentrations were held constant in each 
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sample at 1%. For measurement, samples were diluted at least 10-fold and 
delivered and analyzed on a BD FACScan flow cytometer. 
To measure the effect of a fluorescent CID2950007 analog (RS-II-79, 
synthesized by Dr. Arterburn and colleagues) on Cdc42 nucleotide binding, a 
single-plex dose-response assay was conducted. Diluted samples were 
measured on a BD FACScan flow cytometer. The fluorescence intensity of 
BODIPY-GTP was detected by FL-1 (λex=488 nm, λem = 530/30 nm). FL-2 
(λex=488 nm, λem = 585/42 nm) was used to measure the fluorescence intensity 
of the fluorophore (HPY490) (136), which quantifies the bound RS-II-79 on 
GTPase. The non-specific binding of the RS-II-79 was measured by incubating 
GST-GSH beads with the fluorescent compound. The intensity of the bona fide 
bound RS-II-79 was calculated as: Mean Channel Fluorescence (Cdc42-GSH beads) – 
Mean Channel Fluorescence (GST-GSH beads). 
Live Cell Imaging 
GFP-actin-expressing MDCK cells were cultured on coverslips to 70-80% 
in DMEM media containing 10% FBS overnight. The next day the coverslip was 
transferred to NuncTM glass bottom dish (Thermo Scientific, Cat #: 150682) in 
DMEM-No Phenol Red (Gibco, Cat #: 31053-028) media with 10% FBS and 
loaded with 10 µM RS-II-79. Confocal images were obtained using a Zeiss 
Axiovert 200M microscope and a 60x oil immersion objective. RS-II-79 (HPY-490) 
fluorescence was monitored with excitation at 480 nm and emission above 
530±30 nm. GFP fluorescence was determined with excitation at 490 nm and 
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emission above 510±10 nm. The fluorescence intensity of RS-II-79 was analyzed 
by Slidebook 5 software.  
HPY490 Labeled RS-II-79 Penetration into MCA 
For multicellular aggregate (MCA) assays, 2,000 SKOV3ip-GFP cells were 
seeded into each well of a Lipidure-coated 96 well plate (NOF America 
Corporation, White Plains, NY) and incubated for 48 hours to allow for the 
formation of MCA. MCAs were transferred to a Nunc Lab-Tek Chambered 
Coverglass 8-well imaging chamber (Thermo Scientific) and treated with 
fluorescently-labeled RS-II-79 (10 µM) to determine drug penetration. Confocal 
images through the center of the spheroid were captured at time points up to 66 
minutes of treatment on a Zeiss Axiovert 200 M inverted confocal microscope 
equipped with a warming chamber to maintain the temperature at 37ºC.  Images 
were analyzed with Zeiss Zen software. 
Statistical Analyses 
Prism 5 software (GraphPad) was used to analyze all data to determine 
statistical significance. One-way ANOVA (Analysis of Variance) with Dunnett’s 
test for multiple comparisons was performed to compare differences between the 
means of each group relative to the control group for all assays. P-values less 
than 0.05 were considered statistically significant. ANOVA was performed on 
these standardized values.  
 31 
 
Results 
R-ketorolac and R-naproxen Inhibit Cdc42 and Rac1 GTPase Nucleotide 
Binding as Allosteric Inhibitors 
To test the capacity of ketorolac (Figure 6A) to inhibit GTPase nucleotide 
binding activity and determine the mechanism of inhibition, a bead based flow 
cytometry assay – which measures the in vitro GTPase nucleotide binding 
activity – was used. First, equilibrium nucleotide binding assays were performed 
under conditions where the tested compound concentration was held fixed 
against increasing concentrations of fluorescent nucleotide. In the presence of R-
ketorolac, both the maximum fluorescence (Bmax) and the apparent dissociation 
constant (Kd) of BODIPY-GTP for Cdc42 and Rac1 changed, which suggests a 
noncompetitive mechanism of action (Figure 6B, 6D, Table 1). S-ketorolac did 
not change the Bmax and the Kd for Cdc42 (Figure 6C, Table 1) and exhibited a 
minor inhibition of Rac1 only at the maximum concentration of 100 µM (Figure 
6E). Single-plex dose-response measurements were used to verify the 
enantiomer selectivity of ketorolac for inhibiting nucleotide binding by Cdc42 and 
Rac1. The nucleotide concentrations in the assay were fixed at the determined 
dissociation constants (Kd ≈ 300 nM). Increasing R-ketorolac concentrations 
reduced BODIPY-GTP binding, with respective EC50 (half-maximal effective 
concentration) values of 1.89×10-5 M for Cdc42 and 2.31×10-5 M for Rac1 (Figure 
6F, 6G). The maximal inhibitory response was ~20% for both GTPases. S-
ketorolac did not exhibit an inhibitory activity against either GTPase under the 
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tested conditions. Together, these findings suggest an enantiomer-selective, 
inhibitory activity of R-ketorolac against the nucleotide binding activity of Cdc42 
and Rac1. Mechanistically, R-ketorolac action is consistent with an allosteric 
inhibition of GTPase nucleotide binding. 
Moreover, single-plex dose-response measurements were used to test the 
effect of R-naproxen on Cdc42 and Rac1 nucleotide binding. The nucleotide 
concentration in this assay was fixed at the determined dissociation constant of 
300 nM. As shown in Figure 7, nucleotide binding to the Cdc42 and Rac1 
GTPases was inhibited by R-naproxen with an EC50 of 18 µM. The maximal 
inhibitory response was ~30% for both GTPases. However, EC50 for the inhibition 
of Rac1 by S-naproxen was higher than 200 µM. S-naproxen exhibited a similar 
EC50 for inhibition of Cdc42 but failed to reach the threshold of 20%. Together, 
these findings demonstrate R-naproxen, but not S-naproxen inhibits Cdc42 and 
Rac1 nucleotide binding, which is consistent with the enantiomer-selectivity of R-
ketorolac.  
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Figure 6. R-ketorolac acts as an allosteric inhibitor to selectively inhibit 
BODIPY-GTP binding to Cdc42 and Rac1 GTPases. (A) Chemical structure of 
R- and S-ketorolac with chiral center noted. (B-C) The presence of R-ketorolac 
changed both the Bmax and the Kd (values are tabulated in Table 1) of BODIPY-
GTP binding to Cdc42 measured under equilibrium binding conditions, while S-
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ketorolac did not affect BODIPY-GTP binding. (D-E) R-ketorolac changed the 
Bmax and the Kd of BODIPY-GTP binding to Rac1 measured under equilibrium 
binding conditions, while S-ketorolac did not affect BODIPY-GTP binding except 
at 100 µM. The equilibrium binding of BODIPY-GTP to the GTPases was 
measured in the presence of 0.1% DMSO or various concentrations of R- or S-
ketorolac (1~100 µM). BODIPY-GTP binding curves were fitted to a hyperbolic 
one-site binding equation from GraphPad Prism 5. (F-G) R-ketorolac in contrast 
to S-ketorolac inhibited BODIPY-GTP binding to Cdc42 and Rac1 GTPases in a 
dose-dependent manner. BODIPY-GTP concentration was fixed at 300 nM for 
these experiments. The inhibition curves were fitted to the sigmoidal dose-
response equation from GraphPad Prism5. In all experiments, GST-Cdc42 or 
Rac1 were immobilized on GSH beads and used to measure BODIPY-GTP 
binding. Bead-associated fluorescence intensity was quantified by flow cytometry 
and used to monitor drug treatment induced changes in nucleotide binding. 
Fluorescence attributed to nonspecific nucleotide binding was subtracted 
accordingly. Quantification of three independent measurements is plotted ± SEM. 
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Table 1    Biochemical properties of Cdc42 and Rac1 nucleotide binding 
(BODIPY-GTP) with R- or S-ketorolac treatment 
 
 
Cdc42 Rac1 
R-ketorolac S-ketorolac R-ketorolac S-ketorolac 
 
Bmax 
0.1% DMSO 1303 ± 38.45 1429 ± 49.49 1594 ± 28.08 1595 ± 23.75 
1 µM 1243 ± 22.98 1436 ± 48.54 1428 ± 21.17 1509 ± 19.02 
10µM 1134 ± 29.46 1426 ± 52.29 1355 ± 26.64 1471 ± 25.36 
100µM 1009 ± 13.20 1388 ± 38.97 1249 ± 23.76 1444 ± 27.02 
      
 
Kd 
0.1% DMSO 303.6 ± 26.56 219.6 ± 24.47 206.2 ± 13.66 230.7 ± 10.93 
1 µM 288.7 ± 16.03 195.8 ± 21.98 185.9 ± 10.59 204.4 ± 8.433 
10µM 226.6 ± 12.42 197.5 ± 23.90 176.1 ± 13.43 193.4 ± 11.06 
100µM 195.6 ± 8.465 186.7 ± 17.54 169.8 ± 11.94 
180.6 ± 11.39 
 
The Bmax and Kd for the nucleotide binding (BODIPY-GTP) values were derived 
from data shown in Figure 6B-6E using Prism 5 software (GraphPad).  
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Figure 7.  R-naproxen selectively inhibits BODIPY-GTP binding by Rac1 
and Cdc42 in vitro. R-naproxen in contrast to S-naproxen and 6-methoxy 
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naphthalene acid (6MNA) inhibited BODIPY-GTP binding to GSH bead 
immobilized GST-Rac1 (A) and GST-Cdc42 (B) GTPase in a dose-dependent 
manner. BODIPY-GTP concentration was held constant at 100 nM for these 
experiments and drug concentrations varied from 10 nM to 100 µM. Bead-
associated fluorescence intensity was quantified by flow cytometry and used to 
monitor drug treatment induced changes in nucleotide binding. The inhibition 
curves were fitted to the sigmoidal dose-response equition using GraphPad 
Prism 5. Quantification of three independent measurements is plotted ± SEM.   
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Molecular Docking of ketorolac and naproxen on Cdc42 and Rac1 GTP 
Bound Shows Enantiomer Selectivity of R-ketorolac-Magnesium Interaction 
A recent structural study of guanine nucleotide exchange factor (GEF)-
mediated nucleotide exchange on Cdc42 by Yang et al. demonstrated the 
importance of a valine residue (1951) in the nucleotide sensing domain of the 
DOCK9 GEF (129).  The insertion of the sensing domain valine occludes the 
critical coordination of Mg2+ by the nucleotide and the consequent reduced 
charge shielding significantly decreases nucleotide affinity and leads to its 
release from the GTPase. The mechanism of Mg2+ exclusion to promote 
nucleotide release is distinct from that of other GEF proteins and is suggested to 
enhance DOCK GEF activity against a broader range of GTPases (129).  
Therefore, Mg2+ exclusion was considered as a possible mechanism for 
destabilization of nucleotide binding by R-ketorolac and R-naproxen through 
docking analyses.  The carboxyl moiety has the potential to neutralize or displace 
Mg2+ from interacting with the nucleotide by forming a competing complex with 
the Mg2+. In Figure 8, docking models based on Mg2+ exclusion used by DOCK9 
GEF to promote nucleotide exchange on Cdc42 and Rac1 support the observed 
stereo-selectivity of R-ketorolac and R-naproxen, in which the carboxyl group is 
more favorably positioned than S-enantiomers to participate in Mg2+ exclusion. 
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Figure 8. Compound docking to Cdc42 based on a magnesium exclusion 
model. The docking model is based on the work of Yang et al., 2009 (129) 
wherein Val1951 in the sensing domain of DOCK9 (dark green ribbon) was 
suggested to reduce nucleotide interaction with Mg2+ via steric hinderance or 
‘exclusion’ and thereby destabilize nucleotide binding to cause release from the 
GTPase active site. (A-B) The crystal structure of Cdc42-GDP in complex with 
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the DOCK9 GEF (PDB ID 2WMN) was used to predict the active site docking of 
(C-D) 6-MNA, (E-F) R-, S-naproxen and (G-H) R-, S-ketorolac. (B, D, F, H) The 
carboxyl moiety in all compounds is proposed to interact with the Mg2+, thereby 
precluding interaction with GDP and reducing binding affinity analogous to 
Val1951. R-naproxen and R-ketorolac are shown in green. 6-MNA, S-naproxen 
and S-ketorolac are shown in rust color. R-enatiomers show more favorable 
interaction with Mg2+ than S-enatiomers due to rotational constraints imposed on 
the carboxylate by the stereocenter. Images provided courtesy of Drs. T.I. Oprea 
and O. Ursu (Division of Translational Informatics, Department of Internal 
Medicine, University of New Mexico).   
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Structure-Activity Relationship (SAR) Determination Using Modified 
Ketorolac Analogs 
The parent scaffold, represented by ketorolac, was modified on the phenyl 
group to afford the initial analogue collection. Analogs bearing changes to the 
phenyl ring moiety of the parent ketolorac were proposed since that functional 
group occupies a lipophilic area in the binding model that would benefit from a 
small appendage (e.g., Me, CF3, or halogen). These small extensions from the 
phenyl ring were proposed to make key contacts within the binding site which 
might alter binding affinity. The activities of derivatives were tested in single-plex 
dose-response assays on Cdc42 and Rac1 GTPase nucleotide binding, and 
EC50 values were determined (Figure 9 and Table 2). In comparison to the parent 
compounds, most compounds exhibited similar magnitudes of inhibition and EC50 
values on GTPase nucleotide binding. Interestingly, derivatives modified by 
trifluoromethyl (SKCM 102026) and 3-thiophene (SKCM 103793) resulted in an 
activation of nucleotide binding on Cdc42 with EC50 values of 2.43×10-8 M and 
2.28×10-8 M respectively. SKCM -101439, modified with a fluorine atom resulted 
in a 2.5-fold increased potency on Rac1 (EC50=5.28×10-6 M), while reducing 
potency on Cdc42. 2-thiophene SKCM-103977 altered the compound activity 
from inhibition to preferential activation of Rac1 nucleotide binding with an EC50 
of 1.98×10-8 M. Similarly, 3-thiophene SKCM 103793 switched the activity from 
inhibition to preferential activation of Cdc42 nucleotide binding with an EC50 value 
of 2.28×10-8 M. Notably, the potency of SKCM 103977 and SKCM 103793 were 
dramatically increased (~100-fold) as activators. The structure of the ketorolac 
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analogs are shown in Table 2 along with a tabulation of their efficacies and 
potencies against Cdc42 and Rac1 nucleotide binding activity. Although 
enantiomeric identity of each pair of compounds is unknown and it is difficult to 
conclude the relationship of enantiomeric selectivity observed between the 
analogs and the parent compound, the structural modification in the phenyl group 
is confirmed to have an effect on the overall GTPase nucleotide binding activity. 
Trifluoromethyl (SKCM 102026) and 3-thiophene (SKCM 103793) resulted in an 
activation of Cdc42 nucleotide binding. This finding supports that lipophilic areas  
play a key role in modulating GTPase activity, possibly by affecting property of 
carboxyl group at the chiral center.  
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Figure 9.  The impact of ketorolac analogs on Cdc42 and Rac1 nucleotide 
binding. Parent compounds – ketorolac (A) were modified on the phenyl with a 
fluorine atom (B), a chlorine atom (C), a methyl group (D), or a trifluoromethyl 
group (E). Alternatively, the phenyl ring was replaced by 2-thiophene (F) or 3-
thiophene (G) rings. These analogs were tested by a single-plex dose-response 
assay to evaluate their activities of nucleotide binding on Cdc42 and Rac1 
GTPases. BODIPY-GTP concentration was fixed at 300 nM. The inhibition 
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curves were fitted to the sigmoidal dose-response equation from GraphPad 
Prism5. In all experiments, GST-Cdc42 or Rac1 were immobilized on GSH beads 
and used to measure BODIPY-GTP binding. Bead-associated fluorescence 
intensity was quantified by flow cytometry and used to monitor drug treatment 
induced changes in nucleotide binding. Quantification of two independent 
measurements is plotted ± SEM,  
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Table 2   Impact of ketorolac analogs on in vitro Cdc42 and Rac1 nucleotide 
binding 
Structure 
Screening 
Center Vial 
Barcode 
Number 
Cdc42 Rac1 
Inhibition(-) 
/Activation(+
) magnitude 
EC50 
Inhibition(-) 
/Activation(+
) magnitude 
EC50 
 
R-ketorolac ~ 20% (-) 1.89×10-5 ~ 20% (-) 2.31×10-5 
S-ketorolac <10% (-)  <10% (-) - 
 
SKCM 101436 < 10% (-) - < 10% (-) - 
SKCM 101439 ~ 30% (-) 1.42×10-4 ~ 20% (-) 5.28×10-6 
 
SKCM 100846 ~ 20% (-) 9.38×10-6 ~ 25% (-) 8.17×10-5 
SKCM 104309 < 10% (-) - < 10% (-) - 
 
SKCM 104402 ~ 20% (-) 5.46×10-5 < 10% (-) - 
SKCM 104352 ~ 20% (-) 6.75×10-6 ~ 20% (-) 4.99×10-5 
 
SKCM 102026 ~ 25% (+) 2.43×10-8 < 10% (-) - 
SKCM 100621 < 10% (-) - < 10% (-) - 
 
SKCM 101671 ~ 31% (-) 1.72×10-4 ~ 20% (-) 3.21×10-4 
SKCM 103977 < 10% (-) - < 10% (+) 1.97×10-8 
 
SKCM 103793 ~ 15% (+) 2.28×10-8 < 10% (-) - 
SKCM 103959 ~ 32% (-) 6.75×10-4 ~ 20% (-) 1.03×10-4 
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The Effect of Ketorolac Analogs on Cdc42 and Rac1 Activation in SKOV3ip 
Cells 
A flow-based GTPase effector binding assay (G-trap, detects and quantifies 
GTPases in the GTP-bound conformation) (135) was performed to test the 
impact of ketorolac analogs on Cdc42 and Rac1 activation in SKOV3ip cells. 
Cells were starved for 2 h, treated with each compound for 2 h, and finally 
stimulated with EGF (10 ng/ml). As shown in Figure 10, in comparison to the 
parent compounds, most derivatives did not alter ketorolac activity, which 
showed similar inhibition efficacies and EC50 values on Cdc42 and Rac1 GTPase 
activation. Notably, the 2-thiophene modified analog (SKCM 101671 and SKCM 
103977) exhibited less enantiomer selectivity on the inhibition of Cdc42. The 
trifluoromethyl (SKCM 102026 and SKCM 100621) resulted in loss of inhibition 
against Rac1 for both enantiomers. SKCM 102026 behaved as an inhibitor in 
cells, having been clarified as an activator in vitro (Figure 9E); behavior is similar 
to screening studies that identified R-naproxen as an activator, while cell based 
studies demonstrated inhibitory activity against Rac1 and Cdc42 (Ref PLoS One). 
The different observed behaviors of SKCM 102026 under different assay 
conditions may be due to the experimental context such as the local 
concentration of Mg2+, nucleotide, and other regulatory proteins (e.g. GEFs, 
GAPs). Thus, compounds identified as activators only through in vitro nucleotide 
binding assays, warrant further study in cell-based assays (137). Importantly, 3-
thiophene (SKCM 103793 and SKCM 103959) exhibited more enantiomeric 
selectivity in the inhibition of both Cdc42 and Rac1 GTPases and the active 
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enantiomer retained the inhibition efficacy (~50%) and similar EC50 values 
compared to the parent compound. Taken together, these results suggest 
trifluoromethyl and 2-thiophene alter ketorolac activity, which may be due to 
changed properties of the carboxyl group at the chiral center. One possibility is 
that the trifluoromethyl group, as a strong electron-withdrawing group, may 
enhance the interaction between the -COOH and Mg2+ by decreasing the 
electron density of the carboxyl group. 3-thiophene, as a strong electron-donating 
group, may reduce the interaction between -COOH and Mg2+ by decreasing the 
acidity of the -COOH. The other possibility is that the trifluoromethyl group might 
actually improve lipophilic stabilization of the parent compound and decrease 
carboxyl magnesium interaction through an electron donating activity, which 
induces the observed increased nucleotide binding on GTPase. In addition, 
thiophene may also interact with Mg2+ directly through the cation-π interaction.  
According to the results of the GTPase nucleotide binding assay and the G-trap 
assay, 3-thiophene modification in the phenyl ring was tolerated and provides 
guidance for developing improved ketorolac derivatives with higher affinity, 
efficacy and enantiomeric selectivity.   
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-continued 
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Figure 10. Ketorolac derivatives exhibit different inhibitory effects on 
Cdc42 and Rac1 activation in SKOV3ip cells. Parent compound – ketorolac (A) 
was modified on the phenyl with a fluorine atom (B), a chlorine atom (C), a 
methyl group (D), or a trifluoromethyl group (E). Alternatively, the phenyl ring was 
replaced by 2-thiophene (F) or 3-thiophene (G) rings. These analogs were tested 
by a GTPase effector binding (G-trap) assay to evaluate their activities on 
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epidermal growth factor mediated Cdc42 and Rac1 activation in SKOV3ip cells. 
In all experiments, SKOV3ip cells were starved in 0% FBS media for 2 h and 
pretreated with individual drugs for 2 h prior to EGF (10 ng/ml) stimulation. 
Activated Cdc42 and Rac1 levels in cell lysates were measured using a flow 
cytometry based GTPase effector binding assay. Flow intensities were 
normalized to untreated controls. Quantification of two independent 
measurements is plotted ± SEM.   
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Table 3    Impact of ketorolac analogs on Cdc42 and Rac1 activation in cell-
based assay  
Structure 
Screening 
Center Vial 
Barcode 
Number 
Cdc42 Rac1 
Inhibition(-) 
/Activation(+
) magnitude 
EC50 
Inhibition(-) 
/Activation(+
) magnitude 
EC50 
 
R-ketorolac ~ 50% (-) 2.58×10-6 ~ 50% (-) 5.87×10-7 
S-ketorolac <10% (-) - <10% (-) - 
 
SKCM 101436 ~ 20% (-) 1.42×10-5 < 10% (-) - 
SKCM 101439 ~ 50% (-) 2.15×10-5 ~ 50% (-) 2.71×10-6 
 
SKCM 100846 ~ 50% (-) 1.13×10-6 ~ 50% (-) 2.03×10-5 
SKCM 104309 ~ 20% (-) 1.54×10-5 < 10% (-) - 
 
SKCM 104402 < 10% (-) - < 10% (-) - 
SKCM 104352 ~ 50% (-) 2.02×10-6 ~ 50% (-) 1.32×10-5 
 
SKCM 102026 < 10% (-) 9.25×10-6 ~ 20% (-) 7.10×10-5 
SKCM 100621 < 10% (-) - < 10% (-) - 
 
SKCM 101671 ~ 30% (-) 1.41×10-6 ~ 50% (-) 1.52×10-6 
SKCM 103977 < 10% (-) - < 10% (-) - 
 
SKCM 103793 < 10% (-) - < 10% (-) - 
SKCM 103959 ~ 50% (-) 1.04×10-6 ~ 50% (-) 5.48×10-7 
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CID2950007 Analogs Inhibit GTP Binding to Cdc42 
CID2950007 has been identified as a noncompetitive allosteric Cdc42 
inhibitor (Avg EC50 2.6 µM), which binds to guanine nucleotide-bound Cdc42, 
induces dissociation of nucleotide, and locks the protein in an inactive 
conformation (104, 138). The related structural analog CID44216842 differs by 
the replacement of phenyl and and 4-methoxyphenyl groups of CID2950007 with 
3-methoxyphenyl and 4-bromophenyl substituents at the 3- and 5-positions of the 
4,5-dihydro-1H-pyrazole core, respectively. CID44216842 exhibited a slightly 
improved EC50 (0.4 µM) although the aqueous solubility was decreased (104, 
138). In preparation for fluorescent modification, three analogs were synthesized 
with modifications to the phenyl ring in the pyrazole 5-position as shown in Figure 
11. The 4-bromophenyl substituent of CID44216842 was selected as the site for 
the introduction of a linking alkylamine moiety that could be conjugated to amine-
reactive fluorophores. The 4-iodophenyl analog AG-II-106 was synthesized as a 
more reactive substrate for the palladium catalyzed carbon-carbon coupling 
chemistry that was envisioned for the installation of a linkage, The latent 
chemical linkage was installed using a Sonogashira coupling reaction with tert-
butyl but-3-yn-1-ylcarbamate to give RS-II-16P. The tert-butylcarbamate 
protecting group was removed using trifluoroacetic acid to give the free amine 
RS-II-24C. The effect of each of these new analogs on the binding of BODIPY-
GTP to Cdc42 was assessed in a bead based flow cytometry assay. In this assay, 
the concentration of BODIPY-GTP was fixed at the Kd concentration of Cdc42 (Kd 
=100 nM). Compared to the parent compound (CID2950007, EC50=1.04×10-6 M), 
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AG-II106 and RS-II-16P showed improved EC50 values of 2.90×10-7 M and 
1.06×10-7 M, respectively, and RS-II-24C exhibited a similar EC50 of 1.23×10-6 M. 
Taken together, all three analogs retained inhibitory activity toward Cdc42 
nucleotide binding with either improved or similar EC50 values and similar 
inhibition efficacies.   
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Figure 11.  CID2950007 analogs inhibit BODIPY-linked nucleotide binding to 
Cdc42. All analogs - AG-II-106 (B), RS-II-24C (C) and RS-II-16P (D) exhibited 
similar potencies and efficacies against Cdc42 nucleotide binding in comparison 
to the parent compound-CID2950007 (A).   
EC50=1.03×10
-6 
EC50=2.90×10
-7 
EC50=1.28×10
-6 
EC50=1.06×10
-7 
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Fluorescent Analog of CID2950007 (RS-II-79) Inhibits Cdc42 Nucleotide 
Binding  
A fluorescent analog of CID2950007 and CID44216842 - RS-II-79 was 
synthesized by modifying AG-II-106 with a linkage connected to a fluorescent 
dye. The amine-reactive N-hydroxysuccinimide ester of a hydrazinylpyridine 
based fluorescent HPY-dye was first reacted with N-(2-(2-(2-
aminoethoxy)ethoxy)ethyl)hept-6-ynamide to give 2-(9H-fluoren-9-ylidene)-3,3-
difluoro-6-((2-(2-(2-(hept-6-ynamido)ethoxy)ethoxy)ethyl)carbamoyl)-2,3-dihydro-
[1,2,4,3]triazaborolo[4,5-a]pyridin-2-ium-3-uide. This hept-6-ynamido compound 
was coupled with the iodophenyl analog AG-II-106 using the Sonogashira 
coupling procedure to give the desired product RS-II-79 in good yield. This one-
step coupling approach for introduction of a fluorescent label was analogous to 
the synthesis of RS-II-16P described in the previous section. RS-II-79 exhibits 
absorption spectra with λabs = 472-490 nm and emission spectra with λemi = 551-
563 nm with characteristically large Strokes shifts (136). Based on the efficacy of 
the model compounds RS-II-16p and RS-II-24C possessing alkynyl linkages in 
that position, RS-II-79 was expected to be a functional probe. RS-II-79 was 
tested for efficacy as a probe for inhibiting guanine nucleotide binding and as well 
for comparatively measuring small molecule interaction and affinity for the Cdc42 
GTPase. Using a single-plex dose response assay, RS-II-79 inhibited BODIPY-
GTP nucleotide binding in a dose-dependent manner with EC50 of 1.07×10-6 M 
and maximum inhibition of ~80% (Figure 12). In comparison to the parent 
CID2950007, the inhibitory activity of RS-II-79 against nucleotide binding to 
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Cdc42 was unchanged, though was slightly reduced compared to CID44216842. 
Additionally, the direct binding of RS-II-79 to Cdc42 was tested by following the 
HPY-dye fluorescence intensity bound to GTPase, which showed an Kd of 
1.90×10-7 M and maximum binding efficacy of 80%. Taken together, these results 
suggest that the fluorescent analog, RS-II-79 retains a similar inhibitory effect on 
the nucleotide binding to Cdc42 in comparison to the parent compound, 
CID29500007. The binding curve of the RS-II-79 demonstrates that the 
compound reduces nucleotide binding by direct binding to Cdc42. These data are 
consistent with CID2950007 being identified as an allosteric inhibitor of Cdc42 
(104, 139).   
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Figure 12. Fluorescent analog of CID2950007 - RS-II-79 (44216842-
Hyptanoic-Dioxy-HPY(490)) inhibits BODIPY-linked nucleotide binding to 
Cdc42. (A) Structure of RS-II-79. (B) RS-II-79 reduced BODIPY-GTP nucleotide 
binding to Cdc42 in a dose-dependent manner with an EC50 of 1.07×10-6 M. (C) 
Fluorescent RS-II-79 specifically interacted with Cdc42 in a dose-dependent 
manner. Based on the one-site binding curve, the Kd was determined as 1.90×10-
7 M. In the flow cytometry assay, the fluorescent intensity of BODIPY-GTP was 
detected by FL-1 (λex=488 nm, λem = 530/30 nm), which quantified the nucleotide 
binding. The fluorescent intensity of the fluorophore (HPY) was detected by FL-2 
(λex=488 nm, λem = 585/42 nm) (136), which quantified bound RS-II-79 on 
GTPase. GST-GSH beads were used in the control experiment and represented 
non-specific binding of the compound. The intensity of the bona fide bound RS-II-
79 was calculated as: Mean Channel Fluorescence(Cdc42-GSH beads) – Mean 
Channel Fluorescence (GST-GSH beads).  
Kd=1.90×10
-7 
EC50=1.07×10
-6 
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Penetration of Multicellular Aggregates (MCA) by RS-II-79 
Since the fluorescent analog RS-II-79 was identified as a Cdc42 specific 
inhibitor interacting at an allosteric binding site of GTPase, a live cell imaging 
study was conducted to test the cellular permeability of RS-II-79. In order to 
investigate the rate of RS-II-79 uptaken by the cell, 2 µl of 10 mM stock 
(dissolved in DMSO) was added to 2 ml of the media. Figure 13 shows GFP-
actin-expressing MDCK cells before and after the addition of RS-II-79 with 
excitation at 488 nm and emission detection in the range 530±30 nm. These cells 
started to take up the RS-II-79 within 2-3 min and continue to rise steadily over 
10 min. Therefore, RS-II-79 was found to have good permeability in cultured cells. 
However, due to the diffuse distribution and low signal-to-noise ratio of the 
fluorescent compound, the exact subcellular localization needs to be further 
confirmed. 
Moreover, the penetration of RS-II-79 into MCA was investigated to 
evaluate the drug diffusion processes that mimic the extracellular 
microenvironment in actual solid tumors. The MCA was formed by 2000 
SKOV3ip cells. Appendix A shows representative images of penetration of an 
MCA by RS-II-79, observed by confocal microscopy. A steady increase in 
penetration depth within the MCA was observed from the periphery toward the 
core of the MCA over time. In addition, the MCA penetration assay was also 
conducted in Doxorubicin at 6 µM and Doxil (liposome-encapsulated doxorubicin) 
at 6 µM. The result (data not shown) shows the penetration ability of RS-II-79 is 
similar to Doxil, but not as good as Doxorubicin. These observations suggest that 
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the fluorescent analog of CID2950007, RS-II-79 penetrates within the MCA in a 
time-dependent manner. A gradually diffused and decreased fluorescence 
pattern from the periphery to center region of the MCA was evident. Penetration 
experiments with longer incubation time (up to 24 h) will need to be performed to 
test whether the RS-II-79 could fully penetrate into the MCA. 
  
 61 
 
 
Figure 13. Distribution of fluorescent RS-II-79 in living cells in a time-
dependent manner. GFP-actin expressing MDCK cells were treated with 
fluorescent RS-II-79 at 10 µM final concentration. (A) Representative images of 
GFP-actin expressing MDCK cell in 10 µM RS-II-79 at 0, 7, and 14 min after 
loading the RS-II-79. (B) Quantification of the uptake of RS-II-79 in MDCK cell 
over time.  
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Conclusion and Discussion 
In this chapter, R-ketorolac and R-naproxen identified from high throughput 
screening and computational simulation are shown to inhibit in vitro BODIPY-
GTP nucleotide binding to Cdc42 and Rac1. Equilibrium binding and single-plex 
dose-response studies demonstrated that the R-enantiomers, but not the S-
enantiomers of selected NSAIDs (ketorolac and naproxen) act as allosteric, non-
competitive inhibitors. A computational simulation was conducted and confirmed 
the enantiomer-selective activity of these NSAIDs. We suggest that [R] α-Me 
carboxylates preferentially interact with magnesium and reduce stabilization and 
promote nucleotide release.  Using ketorolac analogs, an SAR analysis was 
initially conducted, which suggests that the phenyl ring plays a key role in 
modulating ketorolac activity on GTPase nucleotide binding, possibly by affecting 
the properties of the carboxyl group at the chiral center. In addition, CID2950007 
derivatives with modifications on the phenyl ring were well tolerated and enabled 
the synthesis of a fluorescent derivative. The fluorescent analog, RS-II-79 has 
similar properties as CID2950007 and is able to permeabilize into single cells 
and penetrate into 3-D tumor MCA.  
The biochemical basis for GTPase inhibition by R-ketorolac and R-naproxen 
is provided by computational and experimental approaches. The model is 
enantiomer-selective, with S-ketorolac being poorly positioned to exert the same 
magnesium exclusion and therefore could explain the observed differences in 
EC50 values measured for R- and S-ketorolac in the in vitro nucleotide binding 
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assay. The model is further supported by X-ray crystallography data, which 
identified the preferential binding of S-naproxen to COX-2 (111). R-naproxen, like 
R-ketorolac, exhibits Cdc42 and Rac1 inhibitory activity, albeit with less potency. 
Naproxen, like ketorolac has a constrained alpha methyl carboxyl that may 
account for the stereo-selective activities of the R- and S-enantiomers (140).  
In preliminary SAR studies, ketorolac analogs were synthesized with 
modifications to the phenyl ring of the parent compound; including additions of a 
methyl group (Me), halogens (F, Cl), trifluoromethyl (CF3) and replacement of 
phenyl with a thiophene. The analogs were tested in vitro using a GTPase 
nucleotide binding assay and in cells using GTPase effector binding assay. 
Because the enantiomeric identity is unknown and the initial compound set was 
fairly limited with modification in a lipophilic area (the phenyl ring), we are unable 
to define a clear SAR trend that improves the activity profile of the parent 
compound in this preliminary study. The fluorine derivatives showed interesting 
trends toward increased Rac1 selectivity over Cdc42 and provide a very sensitive 
nucleus that can be effectively exploited in 1D NMR experiments to probe direct 
binding of small molecule inhibitors to unlabeled GTPase samples and assess 
stoichiometry. However, the 3-thiophene analog shows the most promising 
results with improved affinity, efficacy and enantiomeric selectivity on both Cdc42 
and Rac1 GTPases. This finding indicates that 3-thiophene modification could be 
a good starting point for further analog syntheses and screening. Further SAR 
work is required to evaluate the substitutons on the adjacent carbon of the phenyl 
ring, modifications to the ketone, or alterations to the fused ring system in order 
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to identify the key structures and improved chemical entities for developing 
effective GTPase regulators.  
The identification of R-ketorolac and R-naproxen as allosteric regulators of 
Cdc42 and Rac1 presents a novel mechanism of action based on stabilization of 
the GDP-bound GTPase that may in part be promoted through interference with 
GEF-mediated activation or by making nucleotide exchange independent of 
regulatory proteins. This potential mechanism is distinct from the currently known 
inhibitors that interfere directly with GEF, GAP or GDI interaction or block 
GTPase membrane association, e.g. farnesyl-transferase (FTI), geranylgeranyl-
transferase (GGTI) and prenyl-transferase inhibitors, which display poor 
selectivity for individual Rho GTPases (141-143). The identified R-ketorolac and 
R-naproxen have been shown to specifically inhibit Cdc42 and Rac1 activation, 
but have no effect on RhoA in cell based GTPase effector binding (G-trap) 
assays (See Chapter 4, Figure 35) (138, 140). Naproxen is clinically only 
available as the S-enantiomer. In contrast, ketorolac is an FDA-approved drug 
and is in active clinical use as the racemic mixture. Thus, R-ketorolac is an ideal 
candidate for drug repurposing and development for cancer therapy. In the 
following chapters, the anti-tumor effect of ketorolac was investigated in cell-
based assays and clinical trials, which confirm Cdc42 and Rac1 as novel targets 
of R-ketorolac and demonstrate benefit in patient outcomes in ovarian cancer 
therapy.   
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CHAPTER 3 
R-KETOROLAC TARGETS CDC42 AND RAC1 AND ALTERS 
OVARIAN CANCER CELL BEHAVIORS CRITICAL FOR INVASION 
AND METASTASIS 
Abstract 
Cdc42 and Rac1 are attractive therapeutic targets in ovarian cancer based 
on established importance in tumor cell migration, adhesion and invasion. 
Despite a predicted benefit, targeting GTPases has not yet been translated to 
clinical practice. R-ketorolac is an established allosteric inhibitor of Cdc42 and 
Rac1. In this chapter, cell-based assays were utilized to determine R-ketorolac 
activity against Cdc42 and Rac1 activation and subsequent biological functions. 
Studies on immortalized human ovarian adenocarcinoma cells (SKOV3ip), and 
primary, patient-derived ovarian cancer cells show R-ketorolac is a robust 
inhibitor of growth factor or serum dependent Cdc42 and Rac1 activation with a 
potency and cellular efficacy similar to small molecule inhibitors of Cdc42 
(CID2950007/ML141) and Rac1 (NSC23766). Furthermore, GTPase inhibition by 
R-ketorolac reduces downstream p21-activated kinases (PAK1/PAK2) effector 
activation by >80%. Multiple assays of cell behavior using SKOV3ip and primary 
patient-derived ovarian cancer cells show that R-ketorolac significantly inhibits 
cell adhesion, migration and invasion. In sum, the evidence demonstrate R-
ketorolac is a direct inhibitor of Cdc42 and Rac1 that is capable of modulating 
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downstream GTPase-dependent, physiological responses, which are critical to 
tumor metastasis. The findings demonstrate the selective inhibition of Cdc42 and 
Rac1 GTPases by an FDA approved drug-racemic ketorolac that can be used in 
humans. 
All the work in this chapter are published: Guo, Y, et al., 2015 Oct;14(10):2215-27. 
doi: 10.1158/1535-7163.MCT-15-0419. Epub 2015 Jul 23. 
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Introduction 
PAK1- Effector of Cdc42 and Rac1 
Serving as molecular switches, Cdc42 and Rac1 control a variety of 
signaling pathways that are central to dynamic actin cytoskeletal assemblies and 
rearrangements that are the underpinnings of cell-cell adhesion, cell migration 
and even transformation (62). P21 activated kinases (PAKs) are well known 
downstream effector proteins of Cdc42 and Rac GTPases. As shown in Figure 
14, inactive PAKs form dimers, where the auto-inhibitory domain (AID) binds to 
the kinase domain which prevents auto-phosphorylation. Cdc42 and Rac interact 
with PAK at the Cdc42/Rac interacting binding motif (CRIB) to disrupt the 
interaction between the AID and the dimer PAK, which in turn leads to a 
conformational change of PAK to an activated monomer and causes auto-
phosphorylation of PAK (144). Activated Group A PAK (PAK1, 2, 3) proteins 
phosphorylate regulatory myosin light chain (MLC) or LIM Kinase (LIMK1) which 
leads to formation of polymerized actin structure, such as focal adhesion 
complex, lamellipodia and filopodia (64, 145). However, other types of PAK (e.g. 
PAK4) lead to the dissolution of stress fiber by decreasing myosin light-chain 
kinase (MLC) phosphorylation (63).   
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Figure 14.  A model for PAK1 activation. Based on the published structure 
(145),  PAK1 contains a N-terminal regulatory domain, including Cdc42/Rac1 
interaction/binding (CRIB) and auto-inhibitory domain (AID), a PAK-interacting 
exchange factor (PIX) and a kinase domain. In inactive state, the PAK is auto-
inhibited through the formation of dimers between the AID and the kinase domain 
to prevent auto-phosphorylation. In the present of GTP-Cdc42/Rac1, the GTPase 
CRIB complex catalyzes phosphorylation of Serine144 at AID, which disables the 
AID-kinase domain interaction and activates the monomeric PAK auto-
phosphorylation kinase domain at Threonine 423. The phosphorylation of Serine 
199 is activated by a PAK-interacting exchange factor (PIX).  
Inactive PAK 
Active PAK 
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Rho GTPases Mediated Cell Motility 
Extracellular matrix (ECM) is composed of multiple fibrous protein, 
including collagen, fibronectin, and laminin, providing structural support and the 
biochemical and biomechanical environment for cell division, growth and 
development (146). Cdc42 and Rac1 are involved in cellular signaling pathways 
that transduce extracellular signals to the assembly of integrin-mediated focal 
adhesion complexes (147). In early adhesion events, integrins through G-protein 
coupled signaling mediate focal adhesion kinase (FAK)-Src kinase complex to 
activate Rac for nascent adhesion to the ECM. Later, activated Rac coordinates 
extensive crosstalk between integrin (particularly α5β1), Src kinases and other 
Rho GTPases, which leads to formation of mature focal adhesions involved in 
cell spreading (60, 148-150) (Figure 15). Downstream effectors of Rho GTPases, 
such as PAK1 and IQGAP are responsible for cadherin-mediated cell-cell 
adhesion, which are significant for the formation of MCA, cell migration and EMT 
(151, 152). Cell-matrix and cell-cell adhesion play critical roles during cancer 
metastasis which is required for the anchoring of malignant MCA to the ECM of 
target abdominal organs (19).  
During tumor metastasis, cell migration is another critical step of cell 
movement that is controlled by Rho GTPases (Figure 15). Activated by 
extracellular stimuli, Rho GTPases stimulate actin polymerization for 
lamellipodium extension and filopodia formation. Lamellipodia are thin, sheet-like 
membrane protrusions at the leading edge. Filoopodia are finger-like protrusions 
 70 
 
that extend from lamellipodium (153). Both are regulated by Cd42 and Rac1 
through Rho GTPase-PAK-LIM kinase (LIMK) and Rho GTPase-WASP/WAVE-
Arp2/3 signaling pathways for actin reorganization and serve to establish cell-cell 
and cell-matrix contact (125, 154). Once the lamellipodia and filopodia contact 
the ECM, focal adhesions form to stably anchor cells to the matrix. At the same 
time, when cells migrate in a 3-D ECM, activated Rho GTPases and Src kinase 
are involved in the formation of invadopodia which are membrane protrusions 
that concentrate matrix metalloproteinases (MMP), e.g. MMP2 and MMP-9, at 
their tips and based on their matrix degradative properties enable cell invasive 
behaviors (149, 155, 156).   
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Figure 15. Cell migration model. Cell migration on 2-D and in 3-D ECM is 
schematized in five steps: (1) Lamellipodium extension at the leading edge – 
actin polymerization at the leading edge of cell. Rac, Cdc42 and Arp2/3 involved. 
(2) Formation of new focal adhesion complex – integrins interact with ECM 
ligands and mediate focal adhesion complex formation. Rac involved. (3) 
Secretion of surface proteases at sites of ECM contact leads to focal proteolysis 
and enables invasion of 3-D matrices; (4) Cell body contraction by actomysin 
complexes; (5) Tail detachment. (Parri, M., Cell Communication and Signaling. 
2010;8:23) 
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Materials and Methods 
Cell and Reagents 
Compounds for dose response assays were obtained as follows: R-
ketorolac (K235600, Toronto Research Chemical Inc), S-ketorolac (K235605, 
Toronto Research Chemical Inc), R-naproxen (Acme Bioscience #A5026, Palo 
Alto, CA), S-naproxen sodium (N5160, Sigma-Aldrich), 6-methoxy-2-napthalene 
acetic acid (6-MNA) (70620, Cayman Chemical, Ann Arbor, MI, USA), 
NSC23766 (204823, Santa Cruz, CA), CID2950007 (71203-35-5, Tocris). GST-
PAK1 protein was from Millipore (14-864). Rat tail type I collagen was obtained 
from BD Biosciences (Cat #: 354265). A polyclonal antibody directed against 
Tks5 (Src tyrosine kinase substrate 5) was obtained from Dr. Rytis Prekeris 
(University of Colorado, Denver) (157). The following commercial antibodies 
were used: mouse mAb (monoclonal antibody) directed against Rac1 from BD 
Transduction Laboratories (Cat #: 610651), mouse mAb directed against Cdc42 
from Santa Cruz (Cat #: sc-8401), FITC (fluorescein isothiocyanate)-conjugated 
mouse mAb directed against EpCAM (epithelial cell adhesion molecule) (clone 
Ber-EP4) from Dako (Cat #: F0860); rabbit polyclonal Cy5-conjucated anti-
CA125 (cancer antigen 125) from Bioss Inc.(Cat #: bs-0091R-Cy5), mouse mAb 
PE (Phycoerythrin)-conjugated anti-CD45 (lymphocyte common antigen 45) from 
eBioscience (Cat #: 12-9459), rabbit polyclonal antibodies directed against 
phospho-PAK1 (Ser144)/PAK2(Ser141) (Cat #: 2606), phospho-
PAK1(Ser199/204)/PAK2(Ser192/197) (Cat #: 2605), phospho-
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PAK1(Thr423)/PAK2(Thr402) (Cat #: 2601) and PAK1 (Cat #: 2602) from Cell 
Signaling Technology. Alexa 488 goat anti-mouse antibody (Cat #: A-11029) and 
Alexa 647 goat anti-rabbit antibody (Cat #: A-21235) from Life Technology, all 
used per manufacturers’ instructions. 
Patient Information 
A Phase 0 trial investigating the use of postoperative ketorolac  was 
reviewed and approved by the University of New Mexico Health Sciences Center 
Human Research Review Committee (NCT01670799 clinicaltrials.gov) (158). 
Informed patient consent was obtained prior to surgery. Eligible patients having 
suspected advanced stage ovarian, fallopian tube or primary peritoneal cancer 
underwent planned optimal cytoreductive surgery. Upon surgical entry into the 
abdomen, ascites fluid was retrieved and residual material was recovered and 
sent fresh to the investigators for processing. Ascites material used for this study 
was from patients confirmed to have stage III or IV at final pathologic diagnosis. 
Nine patient samples were included in the study (Table 4). 
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Table 4    Patient Information 
 
Patient 
number 
Tumor 
stage 
Assay application 
Cdc42 
activity 
Rac1 
activity 
Filopodia 
formation 
Cell 
adhesion 
Gelatin 
degradation 
INST1115-
24 IIIC       
INST1115-
29 IIIC        
INST1115-
30 IV        
INST1115-
31 IV*        
INST1115-
35 IIIC        
INST1115-
36 IIIC        
INST1115-
42 IIIC         
INST1115-
43 IIIC         
INST1115-
44 
Unstaged*
*        
INST1115-
49 IIIC       
 
All except for two patients had ovarian serous carcinoma.  
* Patient #30 had stage IV uterine serous carcinoma.   
** Patient #44 had mucinous ovarian cancer. 
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Isolation and Cell Culture of Ascites-Derived Primary Ovarian Cancer Cells 
Peritoneal ascites were obtained at the time of debulking surgery with an 
average volume of 200 ml. Cells were collected by centrifugation at 300g for 5 
min. The Ficoll-Paque (1.073 ± 0.001 g/ml) PREMIUM density gradient media 
(GE Healthcare) was used to pellet and remove erythrocytes and 
polymorphonuclear cells. The mononuclear white cells and tumor cells found at 
the top of the Ficoll interface were transferred to a sterile tube and washed with 
RPMI 1640 media with 5% FBS. To deplete leukocytes and further enrich tumor 
cells, samples were incubated with CD45-coated Dynabeads® (Life technologies, 
Cat #: 11350D) for 1.5 h at 4 °C, washed and collected by centrifugation 
according to the manufacturer’s protocol. Isolated tumor cells were cultured as 
described by T. Shepherd et. al (159). Briefly, enriched ovarian cancer cells were 
cultured on collagen-coated (20 µg/cm2) tissue culture dishes. After 3-4 d, when 
most of the tumor cells had adhered, the media was replaced and continued to 
be changed every 2-3 d until cells grew to confluence. The expanded cells were 
used for filopodia formation, cell adhesion, migration and extracellular matrix 
degradation assays. 
Flow Cytometric GTPase Effector Binding Assay for Quantification of 
Cellular, Active GTPase Levels 
The assay was carried out according to the protocols described previously 
(135). Ketorolac treated and vehicle-control cells were lysed in RIPA (high 
stringency cell lysis buffer) buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 
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0.25% (w/v) Na-deoxycholate, 1 mM Na3VO4, 1 mM NaF, 1% (v/v) NP-40 (nonyl 
phenoxypolyethoxylethanol), 1 mM PMSF (phenylmethylsulfonyl fluoride) and 
protease inhibitors consisting 10 µg/ml each of chymostatin, leupeptin, pepstatin 
and antipain). Insoluble debris was removed by centrifugation and the 
supernatants were incubated with GTPase effector coated beads (PAK1-PBD for 
Cdc42 and Rac1) for 1 h. Primary antibodies directed against Cdc42 or Rac1 and 
secondary antibody Alexa 488 were incubated with the beads for 1 h. 
Fluorescence intensity MCF (mean channel fluorescence) was used to measure 
the amount of active intracellular GTPase. MCF was measured by flow cytometry 
(Accuri C6, BD Biosciences). GTPase activity was calculated as (MCFsample group – 
MCFunstimulated negative control) / MCFstimulated positive control. 
Quantification of Filopodia Formation 
The assay was conducted as described previously (104). Cells were 
cultured on coverslips to 50% confluence and serum-starved for 2 h, treated with 
individual drugs and stimulated with 10 ng/ml EGF for 20 min. Cells were gently 
rinsed 3x with ice cold PBS and fixed with 3% paraformaldehyde. Rhodamine 
phalloidin (ThermoFisher Scientific, Cat #: R415) was used to label the actin. 
Images were collected using a Zeiss LSM (laser scanning microscope) 510 
confocal microscope equipped with a 63× oil immersion lens. For each 
experiment, a battlement pattern was used to select 30 images at random. 
Length and number of filopodia per cell were quantified using Slidebook 5.5 
software. 
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Cell Adhesion Assay 
The adhesion assay was modified from the method described by M.J. 
Humphrie (160). Cells were cultured at least 48 h and disassociated with 0.05% 
trypsin/EDTA. Suspended cells were rested in 0% FBS RPMI media for 1 h and 
treated with individual drugs. Cells stimulated with 5% serum were seeded on a 
96-well plate (5×104 cells/well) coated with 0.5 µg/cm2 fibronectin or collagen and 
permitted to attach for 1 h. The 96-well plate was gently washed with PBS and 
cells were fixed with 3% paraformaldehyde. Samples were stained with crystal 
violet and lysed with 10% acetic acid and absorbance (λ=595 nm) quantified 
using on a plate reader. 
Cell Migration Assay 
SKOV3ip cells were plated at 1x105 cells/well in 24-well Boyden chambers 
and allowed to attach for 4 h. Ketorolac enantiomers were added from 10 mM 
DMSO stocks to growth media at final concentrations ranging from 1 to 300 µM. 
After 48 h, inserts were removed and stained with DAPI (4’,6-diamidino-2-
phenylindole). Final DMSO concentration should be no higher than 0.1%. 
Membrane filters were imaged on a Zeiss inverted microscope using a 20x 
objective. Three representative fields were counted from each treatment group. 
Gelatin Degradation Assay 
The commercial gelatin degradation kit (Millipore, Cat #: ECM671) was used 
per manufacturer’s instructions and modified to incorporate drug treatment and 
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EGF stimulation as follows. Briefly, according to the manufacturer’s instruction, 
poly-L-lysine was diluted for coating pre-cleaned (e.g. acid washed with 15 min 
sonication in waterbath) 12 mm diameter round coverslips (50 µl/coverslip) for 20 
min. 50 µl diluted glutaraldehyde was next placed on coverslips for 15 min. Cy3-
gelatin and unlabeled gelatin were mixed and 25 µl/coverslip was placed on 
parafilm and glutaraldehyde coated coverslip placed carefully face down on top 
of the drop – taking care to avoid trapping air bubbles – and allowed to set for 10 
min in a humidified chamber. Coated coverslips were lifted gently by adding 500 
µl PBS underneath and then incubated with 70% ethanol for 30 min to sterilize, 
protected from light. To quench residual free aldehydes, 500 µl growth media per 
well was added and incubated for 30 min. Cells were seeded on fluorescent 
coverslip and allowed to adhere for 6 h and then treated with individual drugs for 
24 h. Cells were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton 
X-100 and immunostained for Tks5. Actin was visualized with FITC-phalloidin. 
Fifteen fields per coverslip were imaged on a Zeiss LSM 510 META with a 63x oil 
immersion objective. Gelatin degradation by invadopodia was analyzed using 
Slidebook 5.5 software. Percent degradation was quantified as: (degradation 
area)/(total cell area) for each image. 
Western Blot 
SKOV3ip cells were serum-starved for 2 h and treated with individual drugs 
for 1 h. After simulation with 10 ng/ml EGF for 20 min, cells were washed with ice 
cold PBS and lysed with RIPA buffer. Cell lysates were processed for SDS-
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PAGE, transferred to polyvinylidene fluoride membranes and individual proteins 
were detected with specific antibodies directed against PAK and phospho-PAK. 
Statistical Analyses 
Prism 5 software (GraphPad) was used to analyze all data to determine 
statistical significance. One-way ANOVA (Analysis of Variance) with Dunnett’s 
test for multiple comparisons was performed to compare differences between the 
means of each group relative to the control group for all assays. P-values less 
than 0.05 were considered statistically significant. For some assays conducted 
on primary ovarian patient samples (GTPase activity measurements and gelatin 
degradation assays), standard z-scores of the values were calculated for each 
patient to minimize large ranges of values and to compare across groups on a 
uniform scale. ANOVA was performed on these standardized values.  
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Results 
R-ketorolac Inhibits Cdc42 and Rac1 Activation in Immortalized and 
Primary Human Ovarian Cancer Cells 
A flow cytometry based assay for quantitatively assessing the levels of 
active GTPases in cell lysates was developed in the Wandinger-Ness and 
Buranda laboratories (135). The assay was used to test the cellular impact of 
ketorolac isoforms on GTPase activation. Maximal Cdc42 and Rac1 activation in 
SKOV3ip cells treated with 10 ng/ml EGF occurred at different times; 20 min for 
Cdc42 and 5 min for Rac1 (Figure 16). Growth factor stimulated activation of 
Cdc42 and Rac1 was differentially inhibited in an enantiomer-selective manner 
(Figure 17). R-ketorolac substantially inhibited growth factor dependent activation 
of Cdc42 and Rac1 in a dose-dependent manner with an EC50 value of 2.577 µM 
for Cdc42 and 0.587 µM for Rac1 (Figure 17, circles). In contrast, even at the 
highest dose of 100 µM, S-ketorolac exhibited limited inhibition (less than 30% of 
maximum by R-ketorolac) of Cdc42 and Rac1 (Figure 17, squares). Enantiomer-
selective inhibition was also found in HeLa cells treated with R-ketorolac (140). 
Control cytotoxicity measurements in three different cell lines (SKOV3ip, OVCA 
429, and OVCA 433) showed <10% inhibition of cell proliferation induced by 
either enantiomer of ketorolac at the highest tested dose and treatment (300 
µmol/L for 96 hours) (data not shown).  
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Figure 16.  Time course of maximal Cdc42 and Rac1 activation in SKOV3ip 
cells upon growth factor stimulation. SKOV3ip cells were cultured overnight to 
reach ~80% confluence, then stimulated with 10 ng/ml EGF for different time 
length (0 - 40 min). The activation was terminated by washing with ice cold PBS. 
Cells were lysed with RIPA buffer and the activated GTPase levels were 
measured using a flow cytometry based GTPase effector binding assay. 
Normalized activities are expressed relative to unstimulated controls.  
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Figure 17. R-ketorolac preferentially inhibits Cdc42 and Rac1 activities in 
SKOV3ip cells. R-ketorolac causes a dose-dependent, enantiomer selective 
inhibition of growth factor stimulated Cdc42 and Rac1 activation in SKOV3ip cells. 
SKOV3ip cells were starved in 0% FBS media for 2 h and pretreated with 
individual drugs for 2 h prior to EGF (10 ng/ml) stimulation. Activated Cdc42 and 
Rac1 levels in cell lysates were measured using a flow cytometry based GTPase 
effector binding assay. Flow intensities were normalized to untreated controls. All 
experiments were repeated three times independently. Results are normalized as 
[(sample MCF—negative control MCF)/positive control MCF], where the negative 
control is the MCF reading obtained using lysates from unstimulated cells, and 
the positive control is the MCF reading obtained from the stimulated cells treated 
with DMSO. Values below zero represent inhibition of GTPase activity in cells to 
below the basal levels (resting cells without EGF stimulation).   
 
  
  
A B 
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The effect of ketorolac was also examined in primary ovarian cancer cells 
purified from patient ascites. Surgery samples were obtained and analyzed as 
part of an approved clinical study (see Materials and Methods and Table 4). 
Primary human ovarian cancer cells were enriched via Ficoll gradient 
centrifugation and depletion of lymphocytes using CD45 Dynabeads. Purified 
primary human ovarian cancer cells were positive for CA125 and EpCAM, which 
are commonly overexpressed in epithelial ovarian carcinomas (Figure 18) (161, 
162). Isolated tumor cells were treated with individual ketorolac isoforms or 
specific Cdc42 and Rac1 inhibitors and the endogenous Cdc42 and Rac1 
activities were tested. Because of the heterogeneity in activity levels of the 
GTPases for individual patient samples, z-scores were used to comparatively 
evaluate the impact of ketorolac on tumor cell GTPase activities from different 
patients. Treatment with 10 µM R-ketorolac reproducibly inhibited both Cdc42 
and Rac1 in a statistically significant manner (Figure 19). The magnitude of R-
ketorolac inhibition of Cdc42 or Rac1 was similar to the inhibition observed in 
positive controls treated with CID2950007, an allosteric Cdc42 inhibitor, or 
NSC23766, a Rac1 inhibitor that interferes with GEF-mediated GTPase 
activation (104, 105). S-ketorolac exhibited limited inhibition and was not 
statistically significant (Figure 19). Taken together, the results demonstrate that 
R-ketorolac is a potent, enantiomer-selective inhibitor of Cdc42 and Rac1 in 
primary human ovarian cancer cells.  
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Figure 18. Characterization of primary ovarian cancer cell marker 
expression by immunofluorescence. (A) Cells were purified via Ficoll gradient 
and negative selection using CD45-Dynabeads. Cells were stained for CA125 
and EpCAM (clone Ber-EP4). (B) Isolated cells were expanded by brief cell 
culture and stained for CA125 and EpCAM (clone Ber-EP4).  
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Figure 19.  R-ketorolac preferentially inhibits Cdc42 and Rac1 activities in 
ascites derived primary human ovarian cancer cells. R-ketorolac causes a 
dose-dependent, enantiomer-selective inhibition of endogenous Cdc42 and Rac1 
activities in primary ovarian cancer cells. Isolated primary ovarian cancer cells 
from three independent patients were treated with drugs for 1 h and processed 
for flow cytometry GTPase effector binding assays to measure the GTPase 
activity. Six patient samples were tested for Cdc42 activity and five patient 
samples were tested for Rac1 activity in response (Table 4). CID2950007 and 
NSC23766 served as Cdc42 and Rac1 specific inhibitors respectively. Plotted 
are z-scores. For individual patient sample, z-score is defined as z=(X - μ)/σ, 
where X is MCF, μ is the mean of X, and σ is the standard deviation of X. 
Quantification of three independent measurements is plotted ± SEM. Statistically 
significant differences are indicated: *p<0.05, **p<0.01, ***p<0.001.
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Inhibition of Cdc42 and Rac1 by R-ketorolac Decreases Activation of 
Downstream p21 Activated Kinases (PAK1/PAK2) 
The impact of R-ketorolac on PAK1/PAK2 effector signaling directly 
downstream of the Cdc42 and Rac1 GTPases was examined (Figure 20). Cells 
stimulated with 10 ng/ml EGF exhibited robust phosphorylation of the Ser144/141 
residues compared to unstimulated control cells. In contrast, there was a dose-
dependent suppression of p-PAK1/PAK2 following R-ketorolac treatment that 
was similar to positive controls treated with Cdc42 or Rac1 specific inhibitors. S-
ketorolac on the other hand had limited effect on p-PAK1/PAK2 levels at either 1 
µM or 10 µM (Figure 20). The expression of total PAK1 was not affected by 
either R- or S-ketorolac treatment (Figure 20). These results demonstrate the 
suppression of p-PAK1/PAK2 paralleled the inhibition of Cdc42 and Rac1 in a 
dose-dependent manner following R-ketorolac treatment; and S-ketorolac 
exhibited no significant inhibition of p-PAK1/PAK2. 
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Figure 20.  R-ketorolac decreases the phosphorylation of 
PAK1(Ser144)/PAK2(Ser141) without affecting total PAK levels. (A) SKOV3ip 
cells were cultured overnight, then starved in 0% FBS media for 2 h and 
pretreated with individual drugs for 2 h followed by EGF stimulation (10 ng/ml) for 
20 min. Representative blots from one of three independent experiments are 
shown. Equal amounts of cell lysate protein were resolved by SDS-PAGE and 
immunoblotted for p-PAK1(Ser144)/PAK2(Ser141). GAPDH served as the 
loading control. Cdc42 inhibitor, CID2950007 and Rac1 inhibitor, NSC232766 
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were used as positive controls. (B-C) Films from three independent experiments 
were quantified by ImageJ analysis. p-PAK1/PAK2 levels were normalized to 
unstimulated controls. Quantification of three independent measurements is 
plotted ±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01, 
***p<0.001.  
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Phosphorylation of PAK1/PAK2 on two further residues (Thr423/402 or 
Ser199/204 / Ser192/197) that are downstream of other signaling pathways were 
also examined. Interestingly, p-PAK1(Thr423)/PAK2(Thr402) and p-
PAK1(Ser199/204)/PAK2(Ser192/197) were reduced by R and S-ketorolac with 
greater variability and less pronounced enantiomeric selectivity (Figure 21). For 
example, R-ketorolac consistently inhibited the phosphorylation at pPAK1/PAK2 
(Thr423) with statistical significance at 1 µM though more variably at 10 µM. S-
ketorolac exhibited statistically significant inhibitory effects at 10 µM against 
Thr432/402, but not against Ser199/204 / Ser192/197. Inhibition of 
phosphorylation by the Rac1 inhibitor NSC23766 and the Cdc42 inhibitor 
CID2950007 was also more modest and failed to reach statistical significance in 
some instances. The explanation for the differences in responsiveness of 
individual phosphorylation sites is likely due to the fact that Ser144/141 is 
localized in an N-terminal regulatory domain and directly interacts with Cdc42 
and Rac1 (Figure 14). While Thr423/402 residues in the catalytic kinase domain 
and Ser199/204/ Ser192/197 adjacent to auto-inhibitory domain are targeted by 
other regulatory molecules in a GTPase-independent manner (145, 163). For 
example, S-ketorolac may inhibit phosphorylation on these sites by affecting 
lipid-dependent stimulation of PAK1/PAK2 (e.g. sphingosine) or through crosstalk 
between COX-1/COX-2 and PI3K signaling and the GTPase-PAK1/PAK2 
pathway (164, 165).  
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Figure 21. Ketorolac inhibition of p-PAK1 (Thr423)/PAK2(Thr402) and p-
PAK1(Ser199)/PAK2(Ser192). (A-D) Quantification of three independent 
measurements of the expression of p-PAK1(Thr423)/PAK2(Thr402) and p-
PAK1(Ser199)/PAK2(Ser192) levels in SKOV3ip cells +/- drug treatments as 
indicated. p-PAK1/PAK2 levels were normalized to unstimulated controls.  
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R-ketorolac Inhibits Cdc42-Dependent Flopodia Formation in SKOV3ip 
Cells and Primary Ovarian Cancer Cells 
Filopodia are membrane protrusions that are constructed of bundled actin 
filaments and directly regulated by Cdc42 (166). Therefore, we tested filopodia 
formation, including numbers and length of filopodia to evaluate the effect of 
ketorolac on cell behaviors. When resting cells were stimulated with 10 ng/ml 
EGF, both numbers and length of filopodia increased with the most striking 
activation seen 20 min post-stimulation. Two concentrations of R-, and S-
ketorolac were tested to take into consideration differential sensitivities of Cdc42 
to the two enantiomers. In comparison to the vehicle treatment group, R-
ketorolac (at both 1 µM and 10 µM concentrations) decreased numbers length of 
filopodia to basal levels and similar to CID2950007; while S-ketorolac only 
showed a significant inhibition on filopodia length at 10µM and did not 
significantly inhibit filopodia numbers at either 1 µM or 10 µM. (Figure 22). These 
results demonstrate that R-ketorolac impedes filopodia formation, which depends 
on the upstream activation of Cdc42. 
Filopodia formation assays performed using primary ovarian cancer cells 
yielded similar results and reinforced the finding of the enantiomer-selective 
effect. R-ketorolac treated primary ovarian cancer cells exhibited significantly 
decreased filopodia numbers and length; while S-ketorolac exerted no inhibitory 
effect (Figure 23).  
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Figure 22. R-ketorolac decreases Cdc42 dependent filopodia formation in 
SKOV3ip cells following EGF stimulation.  (A) Representative confocal 
images of filopodia formation for each treatment group in SKOV3ip cells are 
shown. Lower panels are magnified images of the boxed regions. (B-C) 
Quantification of numbers and length of filopodia on each cell. For all 
experiments, cells were plated on coverslips and cultured overnight, then starved 
in 0% FBS media for 2 h and pretreated with drug or 0.1% DMSO vehicle for 2 h, 
followed by EGF (10 ng/ml) stimulation for 20 min. Cells were permeabilized and 
stained with rhodamine-phalloidin. Confocal images were taken on a Zeiss LSM 
510 META confocal microscope. All quantification is based on three independent 
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trials with 30 cells imaged in a battlement pattern and analyzed using Slidebook 
5.5 software. Mean lengths or numbers of filopodia are plotted ±SEM. 
Statistically significant differences are indicated: *p<0.05, **p<0.01, ***p<0.001.  
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Figure 23. R-ketorolac decreases Cdc42 dependent filopodia formation in 
primary human ovarian cancer cells following EGF stimulation.  (A) 
Representative confocal images of filopodia formation for each treatment group 
in primary human ovarian cancer cells are shown. Lower panels are magnified 
images of the boxed regions. (B-C) Quantification of numbers and length of 
filopodia per cell in primary human ovarian cancer cells. For all experiments, cells 
were plated on coverslips and cultured overnight, then starved in 0% FBS media 
A 
C B 
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for 2 h and pretreated with drug or 0.1% DMSO vehicle for 2 h, followed by EGF 
(10 ng/ml) stimulation for 20 min. Cells were permeabilized and stained with 
rhodamine-phalloidin. Confocal images were taken on a Zeiss LSM 510 META 
confocal microscope. All quantification is based on three independent trials with 
30 cells imaged in a battlement pattern and analyzed using Slidebook 5.5 
software. Mean lengths or numbers of filopodia are plotted ±SEM. Statistically 
significant differences are indicated: *p<0.05, **p<0.01, ***p<0.001.  
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R-ketorolac Inhibits Cdc42- and Rac1-Mediated Cell Adhesion, Migration 
and Invasion 
Cell Adhesion - A cell attachment assay was used to test the effect of ketorolac 
on cell adhesion. Stimulated cells were allowed to adhere to matrix-coated 
substrates. R-ketorolac reduced SKOV3ip cell adherence to both fibronectin and 
collagen, and S-ketorolac had no significant effect (Figure 24A-B). R-ketorolac 
also inhibited human primary ovarian cancer cell adhesion to collagen; while S-
ketorolac had no significant effect (Figure 24C). This observation suggests that 
the R-enantiomer of ketorolac inhibits cell-substrate adhesion likely as a 
biological consequence of its inhibitory effect on upstream Cdc42 and Rac1 
activation.  
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Figure 24.  R-ketorolac inhibits cell-substrate adhesion in SKOV3ip cells 
and primary human ovarian cancer cells. (A-B) R-ketorolac significantly 
inhibits cell adhesion in SKOV3ip cells compared to S-ketorolac. SKOV3ip cells 
were trypsinized, starved in 0% FBS media for 1 h, pretreated with drug for 1 h, 
A 
C 
B 
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followed by serum stimulation (5% (v/v) final concentration) and seeded on 
matrix pre-coated 96-well plate for 1 h. Cells were fixed and stained with crystal 
violet and finally lysed with acetic acid. Cell substrate adhesion was quantified 
based on absorbance of cell lysates at 595 nm and normalized to unstimulated 
controls. (C) Similar to SKOV3ip cells, R-ketorolac significantly inhibits cell 
substrate adhesion in primary human ovarian cancer cells as well. Primary 
ovarian cancer cells were purified, cultured and used for the cell attachment 
assays to test the effect of drugs on cell substrate adhesion. CID2950007 and 
NSC23766 served as positive controls. Each group was normalized to 
unstimulated controls as [(sample absorbance—negative control absorbance) / 
positive control absorbance], where the negative control is the absorbance 
reading obtained using lysates from unstimulated cells, and the positive control is 
the absorbance reading obtained from the stimulated cells treated with DMSO. 
Value zero represents the basal level (resting cells without serum stimulation) of 
adhesion.  Data represented three independent trials. Each data point represents 
the mean of measured values ±SEM. Statistically significant differences are 
indicated: *p<0.05, **p<0.01, ***p<0.001.  
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Cell Migration - Activated by extracellular stimuli and dependent on GTPase 
activation, cell migration is initiated by the formation of membrane protrusions, 
including Cdc42-dependent filopodia and Rac1-mediated lamellipodia (125). 
SKOV3ip cell migration in the presence of R- or S-ketorolac was tested in a 
Boyden chamber assay. Migration was inhibited in a dose-dependent manner 
with R-ketorolac beginning to impinge on cell migration at 1 µM. The inhibitory 
effect increased in a dose-dependent manner with maximum inhibition of  80% at 
300 µM R-ketorolac (Figure 25). Modest inhibition by S-ketorolac was detected at 
about 50 µM with a maximum inhibition less than 50% at 300 µM. The results 
demonstrate that cell migration was inhibited as a direct biological consequence 
mediated by Cdc42 and Rac1 inhibition by R-ketorolac, whereas S-ketorolac was 
50-fold less potent.  
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Figure 25. R-ketorolac seletively inhibits cell migration in a dose-dependent 
manner. SKOV3ip cells were seeded in Boyden chambers in the presence of 
drug for 48 h. Cell migration was normalized to no treatment controls. Three 
fields of view were counted for each treatment group. Data represented three 
independent trials. Each data point represents the mean of measured values 
±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01, 
***p<0.001. Data provided courtesy of Dr. S.R. Kenney (Department of 
Pharmaceutical Sciences, University of New Mexico).  
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Cell Invasion - Invadopodia are membrane protrusions that are dependent on 
activated Cdc42 and Src kinase. Invadopodia concentrate matrix 
metalloproteinases at their tips and based on their matrix degradative properties 
serve as surrogates for cell invasive behaviors (155). To study the effect of 
ketorolac on invadopodia formation, the invadopodia-mediated degradation of 
gelatin matrices was quantified. In Skov3ip cells, invadopodia were observed as 
puncta of F-actin and Tks5-positive structures, which colocalized with the 
degradation sites on the gelatin matrix (Figure 26A). R-ketorolac treatment also 
resulted in reduced gelatin degradation in a dose-dependent manner with 70 to 
80% inhibition at 1 and 10 µM. However, S-ketorolac did not exert any obvious 
inhibition of gelatin degradation at 1 µM and the reduction of gelatin degradation 
with 10 µM S-ketorolac treatment was ~50% but failed to reach the statistical 
significance (Figure 26 B, C). Tks5 is an early marker of invadopodia formation 
that precedes matrix metalloprotease localization to the tips of mature structures. 
To distinguish whether R-ketorolac had a direct inhibitory effect on 
metalloprotease activity or whether the observed effect on gelatin degradation 
was primarily due to inhibition of invadopodia formation, the impact on 
metalloproteinase activity secreted into the culture medium was also measured 
and found to be similar ± ketorolac. Therefore, we conclude that the primary 
effect of R-ketorolac is to prevent Cdc42-dependent invadopodia formation. 
When the gelatin degradation assay was conducted in primary ovarian cancer 
cells, the standardized z-scores showed the degradation of matrix by tumor cells 
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was also significantly decreased in a dose-dependent manner by R-ketorolac 
treatment, while the inhibition by S-ketorolac was less and reached significance 
only at the highest dose (Figure 27). Z-scores were used to account for large 
differences in absolute GTPase activity levels observed for individual patient 
samples (Figure 19), likely related to known differences in GTPase 
overexpression seen in ovarian cancer (77, 86). The inhibitory effect of R-
ketorolac in primary ovarian cancer cells is consistent with the observations in 
SKOV3ip cells. 
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Figure 26. R-ketorolac inhibits invadopodia formation and gelatin 
degradation in SKOV3ip. (A) Colocalization of gelatin degradation, actin and 
Tks5 antibody in SKOV3ip cells. Insets are magnified images of the boxed 
C 
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regions. Arrowheads denote points of invadopodia formation that are coincident 
with gelatin degradation. (B) Representative confocal images of gelatin 
degradation for each treatment group in SKOV3ip cells are shown. Lower panels 
are magnified images of the boxed regions. Arrowheads denote the gelatin 
degradation sites. (C) Quantification of the gelatin degradation area in SKOV3ip 
cells. For all experiments, SKOV3ip cells were seeded on Cy3-gelatin labeled 
coverslips for 24 h in the presence of different drugs, including two enantiomers 
of ketorolac, and Cdc42 and Rac1 specific inhibitors (CID2950007 and 
NSC23766, respectively) as positive controls. DMSO (0.1%) served as the 
vehicle control treatment. Results are normalized as [(sample degraded area—
negative degraded area) / positive control degraded area], where the negative 
control is the degradation of unstimulated cells, and the positive control is the 
degradation of the stimulated cells treated with DMSO. Value zero represents the 
basal level (resting cells without EGF stimulation) of gelatin degradatiion. All 
quantification is based on three independent trials with 15 representative fields 
counted for each treatment. Each data point represents the mean of measured 
values ±SEM. Statistically significant differences are indicated: *p<0.05, **p<0.01, 
***p<0.001.  
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Figure 27.  R-ketorolac inhibits invadopodia formation and gelatin 
degradation in primary human ovarian cancer cells. (A)  Representative 
confocal images of gelatin degradation for each treatment group in primary 
ovarian cancer cells are shown. Lower panels are magnified images of the boxed 
regions. Arrowheads denote the gelatin degradation sites. (B) Quantification of 
the gelatin degradation area in primary ovarian cancer cells. Due to the variability 
A 
B 
 106 
 
of the extent of gelatin degradation observed with primary human ovarian cancer 
cells, z-scores are plotted. For all experiments, primary ovarian cancer cells were 
seeded on Cy3-gelatin labeled coverslips for 24 h in the presence of different 
drugs, including two enantiomers of ketorolac, and Cdc42 and Rac1 specific 
inhibitors (CID2950007 and NSC23766, respectively) as positive controls. DMSO 
(0.1%) served as the vehicle control treatment. Plotted are z-scores. For 
individual patient sample, z-score is defined as z=(X - μ)/σ, where X is the gelatin 
degraded area for each treatment, μ is the mean of X, and σ is the standard 
deviation of X. All quantification is based on three independent trials with 15 
representative fields counted for each treatment. Each data point represents the 
mean of measured values ±SEM. Statistically significant differences are indicated: 
*p<0.05, **p<0.01, ***p<0.001.  
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Conclusion and Discussion 
In this chapter, R-ketorolac is shown to inhibit Cdc42 and Rac1 activation 
and associated cell functions, including adhesion, migration and invasion in both 
SKOV3ip cell and primary human ovarian tumor cells. In its clinical application, 
ketorolac is given for its potent analgesic activity. It is administered as a racemic 
mixture via diverse routes (intravenous, injectable, oral, intranasal) and is known 
as ToradolTM. The pain relieving activity is ascribed primarily to the S-enantiomer, 
which is a known non-selective cyclooxygenase (COX-1/COX-2) inhibitor (122, 
167). The R-enantiomer lacks significant activity against cyclooxygenases (e.g. 
IC50 >100 µM against COX1 and COX2 and ~3 orders of magnitude greater than 
the IC50 of S-ketorolac) and has until now been considered inert (122, 167). The 
previously unrecognized and novel mechanism of action for the R-enantiomer 
has important ramifications when considering the efficacy and novel activities of 
clinically administered ketorolac. For example, breast cancer patients treated 
with ketorolac perioperatively had a decreased rate of early breast cancer 
relapse (53). Collaborative studies from Hudson and Wandinger-Ness 
laboratories with collogue Muller and Cook demonstrate ovarian cancer patients 
receiving ketorolac exhibit an enrichment of R-ketorolac in the peritoneum, a 
reduction in GTPases activation of residual tumor cells, and improved 5-year 
survival (86). The cell based studies using human immortalized and primary 
human ovarian cancer cells presented here, demonstrate that R-ketorolac 
treatment alters tumor cell adhesion, migration and invasion—all behaviors that 
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are central to ovarian cancer metastasis. The findings offer unprecedented 
mechanistic insights regarding the R-ketorolac activity against GTPases, which 
may explain the clinically observed survival benefit in patients treated 
perioperatively with racemic ketorolac. 
In ovarian cancer, cyclooxygenases are upregulated and have been 
considered as potential targets, however, clinical trials have been mixed and do 
not support significant benefit in combinatorial treatment with chemotherapy and 
a cyclooxygenase inhibitor versus treatment with chemotherapy alone (168). 
Although the survival benefit of ketorolac use in breast cancer was postulated to 
be due to possible inhibitory roles in anti-angiogenesis, inhibition of prostaglandin 
synthesis and decreased immune suppression as compared to opioids and other 
analgesics (169, 170), there was previously no precedence for other 
pharmacologic activities associated with R- or S-ketorolac. A recent structural 
study identifies a new hydrophobic ligand binding site on intestinal fatty acid 
binding protein that can interact with ketorolac (all deposited structures show 
protein complexed to R-ketorolac though not explicitly stated in publication – 
Ursu and Oprea, unpublished observation), though functional consequences are 
unknown (170). We speculate that the slight inhibitory effects of S-ketorolac on 
GTPase activation and actin dependent cell behaviors may arise from crosstalk 
between COX-2 and PI3K and integrin regulated pathways. COX-2 dependent 
crosstalk has been shown through knockout and pharmacologic means to 
regulate Cdc42 and Rac1 activation, and adhesion and migration of 
macrophages and endothelia (165, 171). Because R-ketorolac is a much less 
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potent COX inhibitor than S-ketorolac, its more pronounced effect on GTPase 
activation and downstream cell behaviors indicates that it is primarily targeting 
Cdc42 and Rac1 through a direct mechanism. Furthermore, pharmacokinetic 
analyses show that S-ketorolac is more rapidly excreted, leading to an increased 
prevalence of R-ketorolac in vivo (86, 122, 167). Taken together, our 
identification of R-ketorolac as a GTPase inhibitor helps to explain the significant 
benefits of racemic ketorolac in human breast and ovarian cancer patient survival, 
and why other NSAIDs that preferentially target COX have not yielded similar 
benefit (53, 86, 172). 
Ketorolac is an FDA (Food and Drug Administration)-approved drug for 
human use and is in active clinical use as the racemic mix. Therefore, R-
ketorolac has significant potential for rapid repurposing. Implementation of R-
ketorolac in human clinical trials would offer the first opportunity to directly test 
the predicted benefit of a Cdc42 and Rac1 selective inhibitor for cancer patients. 
Such an application could circumvent current renal and hematologic toxicities 
that limit racemic ketorolac use to a maximum of 5 days. Analyses of Rac1 
inhibition in cancer cell lines and animal models with NSC23766 treatment 
suggests benefit for inhibiting metastasis and angiogenesis (173). Additionally, 
Rac1 inhibition may mitigate Trastuzumab resistance in breast cancer cell lines, 
thus suggesting that the availability of a clinically accessible selective Cdc42 and 
Rac1 inhibitors could offer new paradigms for combinatorial therapies (173). We 
envision that the use of R-ketorolac in the perioperative window and thereafter 
presents a unique opportunity to block tumor reseeding and spread, as well as 
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angiogenesis, which may enhance the efficacy of combined chemotherapies or 
targeted therapies. 
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CHAPTER 4 
A NOVEL PHARMACOLOGIC ACTIVITY OF KETOROLAC FOR 
THERAPEUTIC BENEFIT IN OVARIAN CANCER PATIENTS 
Abstract 
Previous studies identified the R-enantiomer of ketorolac as an inhibitor of 
the Rho family GTPases Cdc42 and Rac1. Cdc42 and Rac1 regulate cancer-
relevant functions including cytoskeleton remodeling necessary for tumor cell 
adhesion and migration. In this chapter, elevated expression and activity of 
Cdc42 and Rac1 are reported in ovarian cancer patient tissues, confirming target 
relevance. A clinical trial is performed in eligible patients to measure the 
bioavailability of R- and S-ketorolac in serum and peritoneal fluid, and GTPase 
activity in peritoneal cells. The results show ketorolac in peritoneal fluids is 
enriched in the R-enantiomer and GTPase activity is inhibited in ascites-derived 
primary ovarian tumor cells after ketorolac administration when R-ketorolac is at 
peak levels.  In addition, a retrospective study suggest that women given 
perioperative  ketorolac  have  a  lower hazard of death (Hazard Ratio=0.30 
[95%CI 0.11-0.88]). Thus, ketorolac has a novel pharmacologic activity conferred 
by the R-enantiomer and R-ketorolac achieves sufficient levels in the peritoneal 
cavity to inhibit Rac1 and Cdc42, potentially contributing to the observed survival 
benefit in women who received ketorolac. 
All the work in chapter 4 are published Guo, Y and Kenney SR, et al.,Clin Cancer 
Res. 2015 Jun 12. [Epub ahead of print] PMID: 26071482 
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Introduction 
Ovarian cancer is the leading cause of death from gynecologic 
malignancies and the second most common gynecologic cancer (174). Five year 
patient survival remains less than 50% and the mortality rate hasn’t changed 
appreciably in two decades (174). The majority of women are diagnosed with 
metastatic disease, and although a substantial proportion of women respond to 
initial treatment, recurrence is common (16). Despite concerted efforts, 
identification of effective targeted therapies has remained elusive in this disease 
(6). There remains a great need to identify new strategies to treat and manage 
ovarian cancer.  
The Rho family of small GTPases (Cdc42, Rac and Rho) are key 
regulators of cancer-relevant cellular functions including actin reorganization, cell 
motility, cell-cell and cell-ECM adhesion and invasion (54, 149, 153). In many 
human tumors (including colon and breast), there is clinical and experimental 
evidence that aberrant Rho-family signaling contributes to tumor growth, survival, 
invasion and metastasis (54, 68, 175-177). On the basis of these functions, 
Cdc42 and Rac1 have been recognized as attractive therapeutic targets (173, 
178) and inhibitors are effective in experimental systems (104, 107-110, 179, 
180), but specific inhibitors of Cdc42 or Rac1 have not been translated to clinical 
use.  
A Cdc42 selective inhibitor effectively blocked migration of two ovarian 
tumor cell lines (104, 181), suggesting that Rho-family GTPases may be potential 
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therapeutic targets in ovarian cancer. Using findings obtained from a high 
throughput screen of the Prestwick library of off patent, FDA-approved drugs and 
cheminformatics approaches, we identified the R-enantiomers of a limited 
number of NSAIDs as inhibitors of Cdc42 and Rac1. The corresponding S-
enantiomers are considered the active component in racemic drug formulations 
acting as NSAIDs with selective activity against cyclooxygenases (COX). One 
candidate, R-ketorolac, inhibited ovarian tumor cell migration and adhesion 
without causing cytotoxicity (182, 183). Our data indicate that the clinically 
administered racemic ketorolac (Toradol®) has two distinct pharmacologic 
activities; the well-established inhibition of COX 1 and 2 by S-ketorolac serving 
as the basis of the FDA-approved indication for pain management, and a 
previously unrecognized property of Cdc42 and Rac1 inhibition conferred by the 
R-enantiomer. Cell based measurement of GTPase activity demonstrated that R-
ketorolac specifically inhibits EGF-stimulated Cdc42 and Rac1 activation at low 
micromolar concentrations. The GTPase inhibitory effects of R-ketorolac in cells 
mimic those of established Cdc42 (CID2950007/ML141) and Rac1 (NSC23766)-
specific inhibitors (104, 183). 
In this chapter, R-ketorolac is shown to achieve an effective concentration 
in peritoneal fluids and inhibited Cdc42 and Rac1 activity in cells retrieved from 
the peritoneal compartment of post-surgical ovarian cancer patients following 
administration of the racemic drug for postoperative pain management. A 
medical record review to compare the ovarian cancer-specific survival of ovarian 
cancer patients who did or did not receive ketorolac for post-operative analgesia 
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revealed increased survival of patients receiving ketorolac. This observation is in 
keeping with reports for improved clinical outcomes associated with ketorolac 
usage, as compared with other NSAIDs, in breast cancer patients (53, 169, 184). 
Although it has been long recognized that R-enantiomers of NSAIDs are poor 
inhibitors of COX activity (167, 185, 186), potential pharmacologic activities or 
benefits of the R-enantiomers have remained largely unexplored. The findings 
show that Cdc42 and Rac1 are unrealized therapeutic targets in ovarian cancer 
and use of ketorolac may benefit ovarian cancer patients.  
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Materials and Methods 
Immunohistochemical Analyses of GTPase Targets 
Immunohistochemical staining was performed using standard procedures. 
Rac1 was stained with mAb (clone 102, BD Biosciences, 10155-1-AP) and 
Cdc42 was stained with rabbit pAb (Protein Tech Group). A Vectastain Ready-to-
Use (RTU) ABC-peroxidase kit and ImmPact DAB (SK-4105) were used to 
visualize primary antibody labeling with hematoxylin nuclear counterstain (H-
3401) for tissue staining and samples were mounted in VectaMount (H-5000); (all 
from Vector Laboratories).  
For large scale ovarian tumor profiling, tissue microarrays were purchased 
from US BioMax, Inc. (Rockville, MD, cat# OV1005 061 and OV8010 009). In 
total180 unique tissue samples were included in the evaluation; ranging from 
stage I-IV and grades 1-3 (Appendix A). All tumor types were validated and 
staining was scored by a pathologist with gynecologic pathology specialty (Dr. 
Lomo) and evaluated for location (nuclear and cytoplasmic), as well as intensity 
of positive staining. Scoring was based on the product of the percentage of cells 
stained and the intensity of the staining in each localization (3+: strong, 2+: 
intermediate, 1+: weak and 0: no staining), resulting in a minimum of 0 (100% 
cells x 0) and a maximum of 300 (100% cells x 3+).   
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qPCR of Ovarian Cancer cDNA Arrays 
qPCR was performed using Origene SYBR Green I master mix solution 
diluted to a final concentration of 1X with primers at a concentration of 0.33μM.  
PCR mix was added to each well of the microarray plate and incubated on ice for 
15m to dissolve the cDNA. qPCR was conducted using a Bio-Rad iCycler 
(Hercules, CA) under the following conditions; 95° for 5m, 30 cycles of (95° for 
15s, 60° for 30s, 72° for 1m), followed by melt curve analysis, hold at 4°.  Rac1b 
levels were measured using custom primers synthesized by Invitrogen. Rac1b 
forward primer, 5’-TCCGCAAACAGTTGGAGA-3’, was coupled with Rac1 
reverse primer, 5’-CTACATGTTTGCGGATAGGATAGGG-3’. The identity of the 
PCR product as Rac1b was confirmed by sequence analysis. 
qPCR of Ovarian Cancer cDNA Arrays 
Rac1b levels were measured using custom primers synthesized by 
Invitrogen. Rac1b forward primer, 5’-TCCGCAAACAGTTGGAGA-3’, was 
coupled with Rac1 reverse primer, 5’-CTACATGTTTGCGGATAGGATAGGG-3’.  
The identity of the PCR product as Rac1b was confirmed by sequence analysis. 
Quantitative PCR (qPCR) of Ovarian Cancer cDNA Arrays 
qPCR analysis of Rho family GTPases was performed using Tissuescan 
Ovarian Cancer cDNA microarrays (Appendix B) from Origene (Rockville, MD, 
cat# HORT301, HORT302,HORT303) and standard techniques. qPCR 
amplification utilized Qiagen Quantitect primers for Cdc42 (Valencia, CA, 
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QT01674442), Rac1 (QT00065856), and RhoA (QT00044723), and β-actin 
(Origene), and custom Rac1b primers from Invitrogen (Carlsbad, CA). Primer 
information for Rac1b, additional information on the Ovarian Cancer cDNA arrays 
is presented in Appendix B. Analysis of serous cancer only is shown in Figure 32. 
CT values obtained using iCycler software. Relative expression levels were 
determined using ΔΔCT values. 
Patients, Study Design and Treatment 
A Phase 0 trial investigating the use of postoperative ketorolac was 
reviewed and approved by the University of New Mexico Health Sciences Center 
Human Research Review Committee (clinicaltrials.gov -NCT01670799). Patients 
presenting with a new diagnosis of ovarian, fallopian tube or primary peritoneal 
cancer were screened for eligibility. Eligible women were at least 18 years old, an 
ECOG Performance Status <2 and had consented to a planned debulking 
surgery- Consent was obtained prior to surgery if primary eligibility was met. 
Secondary eligibility after surgery included confirmed histologic diagnosis of 
epithelial ovarian, fallopian tube or primary peritoneal cancer; optimal 
cytoreduction and placement of an intraperitoneal port for planned chemotherapy; 
adequate renal function and no postoperative complications prohibiting ketorolac 
use. Patients with known bleeding disorders or other contraindications to NSAID 
use were excluded. 
Subjects received a single IV dose of Toradol® (15 or 30 mg based on the 
patient age and creatinine clearance) within the first 72 h of surgery when all 
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clinical safety parameters were met. Use of other NSAIDs during the trial was not 
permitted; however narcotic regimens were allowed for postoperative pain 
management. All study protocols were reviewed by an independent data and 
safety monitoring board. Baseline ascites samples were obtained at surgery. 
Subsequent peritoneal fluid samples were collected from the intraperitoneal port 
prior to dosing and at 1, 6, and 24 h after single dose ketorolac administration. 
Peripheral blood was collected at the same time points. Serum and peritoneal 
fluid were separated from cellular material via low speed centrifugation. Tumor 
cells were further purified on Ficoll gradients to red blood cells and negative 
selection with anti-CD45 beads to remove lymphocytes. The resulting tumor cell 
fractions were analyzed by flow cytometry for EpCAM and MUC16/CA125 (see 
Figure 28 for representative purity). 
Analysis of Patient Derived Cells 
To purify ovarian cancer cells from ascites, cells were recovered from 
ascites samples by low speed centrifugation at 1000 rpm. The cell pellets were 
gently resuspended and overlaid on a Ficoll (density 1.077±0.001 g/ml; GE 
Healthcare 17-5442-02) to separate red blood cells from lymphocytes and tumor 
cells per manufacturer's instructions.  Anti-CD45 beads (ThermoFisher Scientific, 
11153D) were used to deplete lymphocytes and the resulting tumor cell fraction 
was analyzed visually and by flow cytometry. For flow cytometric analysis, cells 
suspended in phosphate buffered saline (PBS) were fixed with formaldehyde (2-4% 
final concentration) for 10 min, chilled for 20 min and then processed for 
immunostaining as described by Cell Signaling Technology 
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(http://www.cellsignal.com/contents/resources-protocols/flow-cytometry-protocol-
(flow)/flow; webpage Accessed July 22, 2014). Briefly, non-specific mAb binding 
to human Fc receptor was blocked by pretreatment for 10 min at room 
temperature with human Fc receptor binding inhibitor (14-916, Affymetrix 
eBioscience).  Conjugated primary antibody staining was performed in PBS 
containing 0.5% BSA using 0.5-1 x106 cells / assay for 1 h at room temperature. 
Cells were washed with 500 µM PBS containing 0.5% BSA once and 
resuspended in 500 µl PBS for flow cytometry measurement (BD FACSCalibur)  
Tumor cell fractions were positive for EpCAM (detected with mAb against 
EpCAM clone Ber-EP4, Dako) and MUC16/CA125 (detected with a Cy5-labeled 
rabbit pAb directed against human MUC16/CA125; bs-0091R-Cy5, Bioss 
Antibodies) and negative for CD45 (detected with a PE-labeled rabbit pAb 
directed against human CD45/LCA, 12-9459, Affymetrix eBioscience) (Figure 28).   
For analysis of GTPase activity in patient-derived cells, active RhoA was 
quantified based on binding to GST-Rhotekin (RT01, Cytoskeleton, Inc.). 
Antibodies specific for Cdc42 (sc-8401, Santa Cruz Biotechnology, Inc.), Rac1 
(610650, BD Transduction Labs) or RhoA (26C4, sc-418, Santa Cruz 
Biotechnology, Inc.) and Alexa Fluor 488 donkey anti-mouse lgG (A21202, Life 
Technologies) were also used. 
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Figure 28.  Purified ovarian tumor cells express EpCAM and MUC16/CA125. 
Ovarian tumor cell identification by flow cytometry using patient ascites samples 
from three individuals (designated 29, 30, and 35). Tumor cells were purified 
from ascites using Ficoll gradients to remove red blood cells and CD45 
Dynabeads negative selection to remove leukocytes. The resulting cells (gated 
as R3) were negative for CD45 and positive for EpCAM and MUC16/CA125.  
Markers were tracked by flow cytometry on a Becton Dickinson FACSCalibur 
Flow Cytometer. 
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High Performance Liquid Chromatography 
R- and S-enantiomers of ketorolac were analyzed by high performance 
liquid chromatography (HPLC) using published procedures (186, 187). See 
Appendex C for additional information. The R-value for the standard curve of 
total ketorolac was 0.9997 and represented a concentration range that spanned 
established human serum concentrations (0.092 μg / ml to 6.0 μg / ml). 
Analysis of GTPase Activity 
Two methods were used to assess GTPase activity in cells based on 
effector binding. Commercial GLISA kits from Cytoskeleton, Inc., analyzed Rac1 
(Denver, CO, cat# BK-128), Cdc42 (BK-127) or RhoA (BK-124) per 
manufacturer’s instructions. Alternatively, Rac1, Cdc42 and RhoA activities were 
measured using a flow cytometric effector binding assay (G-trap) (135, 140). 
Briefly, ~105 purified primary tumor cells were lysed in 200 µl RIPA buffer for 
each assay. GST-PAK1 protein (Millipore, 14-864) was immobilized to the GSH-
beads according to the methods reported in previous work (180). Cell lysates 
were normalized to the same concentration and incubated with pre-labeled 
beads for 1 h at 4ºC. Primary antibody and conjugated secondary antibody 
staining were performed in HPS buffer containing 1% BSA for 1 h at 4ºC. Stained 
beads were resuspended in 500 µl HPS buffer. Fluorescence intensity (mean 
channel fluorescence, MCF) was measured by flow cytometry (Accuri C6). 
GTPase activity was calculated by (MCF of sample group – MCF of unstimulated 
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group) / MCF of stimulated group. Equal amounts of protein were used for each 
assay. 
Retrospective Patient Outcomes Review 
A medical record review was conducted under institutional review board 
approval with a waiver of patient consent. Ovarian cancer patients were identified 
from the New Mexico Tumor Registry [NMTR] a member of the population-based 
Surveillance, Epidemiology, and End Results [SEER] Program of the National 
Cancer Institute (34). Inclusion criteria were as follows: invasive, epithelial 
ovarian cancer (any histology), age 40-79 years at diagnosis, years of diagnosis 
2004–2006, and receipt of surgery at an Albuquerque, NM hospital (only three 
hospitals in the metropolitan area provide this level of surgery). Diagnosis years 
of 2004-2006 ensured at least 6 years follow-up (mortality followed through Dec 
31, 2012) for each patient. We abstracted the surgical medical records for all 
analgesics and anesthesia medications used before hospital admission, during 
surgery and hospital stay, and given at discharge. Of the 138 potential cases, 6 
women did not undergo surgery because of advanced disease/severe 
comorbidities or desired palliative care only, 1 woman had her surgery in another 
state, 2 women died before surgery, and medical records were not located for 
6women, leaving 123 women in the final analysis. 
Statistical Analysis 
qPCR findings for GTPase expression levels were analyzed using one-
way ANOVA followed by Dunnett’s Multiple comparisons test to determine 
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differences between ovarian cancer grade. IHC data was analyzed using one-
way ANOVA followed by Tukey's post test to determine significant differences 
between groups. Data obtained from patient fluid and cell samples was analyzed 
as a repeated measure ANOVA followed by Dunnett’s multiple comparisons test 
to determine significant differences between groups. For the retrospective 
medical record review, information from the medical record was merged with 
information from the NMTR for final analysis. Clinical and treatment 
characteristics of patients who did and did not receive peri-operative ketorolac 
were compared with chi-square tests and t-tests. In a preliminary, crude analysis 
the Kaplan-Meier method was used to estimate the survival probabilities. The 
difference in survival based on receipt of peri-operative ketorolac was examined 
using the stratified log-rank test to adjust the effect of a single categorical factor 
such as age group, AJCC stage, etc. Because this was an observational study 
and not a randomized controlled trial, the final analysis was based on a Cox 
proportional hazards model to adjust for clinical and treatment characteristics that 
may have differed between those who did and did not receive peri-operative 
ketorolac. We estimated the hazard ratio (HR) for ovarian cancer-specific 
mortality comparing those who did and did not receive peri-operative ketorolac 
while adjusting for age at diagnosis (<50, 50-64, >65) AJCC stage (I, II, III, IV), 
completion of chemotherapy as planned (yes, no), and receipt of neoadjuvant 
chemotherapy (yes, no). Based on the Cox proportional hazards regression, an 
example survival plot is presented in Figure 36. Additional survival plots are 
presented in Appendix C-F.  
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Results 
Expression of Rac1 and Cdc42 in Ovarian Cancer 
On the basis of the established functions of Rho-family GTPases, ovarian 
cancer metastasis is predicted to be strongly dependent on Rac1/Cdc42-
regulated pathways for exfoliation, formation of multicellular aggregates, 
mesothelial adhesion, and localized invasion into the interstitial collagen-rich 
submesothelial matrix (6, 16, 188). To test whether these GTPases are 
dysregulated in ovarian cancer, we examined grade-dependent expression of 
Cdc42and Rac1 protein by immunohistochemical staining of human tumor 
samples (Figure 29) and GTPase mRNA using quantitative PCR analysis of 
ovarian cancer tissue cDNA arrays (Figure 30 and Figure 31). Cdc42 protein 
overexpression levels were highly significant for malignant, high grade tumors 
(p<0.001) compared to lower grade tumors without an apparent increase in 
mRNA levels. In contrast, there was little evidence of increased expression of 
Rac1 protein with increasing grade (Figure 29). However, significantly elevated 
expression of a constitutively active splice variant Rac1b (36-38) was detected in 
ovarian tumors (Figure 30). These findings provide evidence for aberrant 
expression of Rac1 and Cdc42 in ovarian cancer and suggest that they may 
represent therapeutic targets for this disease.  
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Figure 29.  Overexpression of Rac1 and Cdc42 protein in ovarian cancer 
specimens. (A-C) Representative images of ovarian serous cancer tissue are 
shown. Clinical characteristics of the samples in the array are provided in Figure 
32. Magnification 200X. Scale bar 20µm. (A) Hematoxylin/Eosin staining (H&E). 
(B-C) Samples were stained with antibodies against Rac1 or Cdc42 and 
avidin/biotin horse radish peroxidase enzyme complex. Controls and tissue 
samples were developed for identical times. (D-E) Tissue pathology and staining 
evaluated by board certified pathologist with gynecologic pathology specialization 
(Lesley Lomo, MD) and statistical analyses by statistician (Ed Bedrick, PhD, 
University of Colorado Denver, Anshutz Medical Campus). For Rac1 one way 
non-parametric ANOVA (p=0.0087) and Tukey post-test shows normal stroma vs. 
intermediate to high grade carcinoma (p<0.05) with all other comparisons non-
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significant. For Cdc42 one way non-parametric ANOVA (p=0.0001) and Tukey 
post-test shows normal stroma and benign to borderline tumor vesus 
intermediate to high-grade carcinoma p<0.05 with all other comparisons non-
significant. Images provided courtesy of Dr. L. Lomo and Ms. E. Romero 
(Department of Pathology, University of New Mexico)  
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Figure 30. Expression of constitutively active Rac1b mRNA is elevated in 
ovarian cancer specimens. Tissuescan ovarian cancer cDNA microarrays 
(Origene) were amplified using primers against Rac1, Rac1b, Cdc42, RhoA, and 
β-actin as described in Patients and Methods. As per the manufacturer's 
description, patients with endometriosis, leiomyoma of myometrium, follicular 
cysts, abscesses, or secretory endometrium, but otherwise healthy ovarian tissue, 
were considered normal (n=19). Tissues defined as low grade have a FIGO 
score of 1 (n=19) or 2 (n=32). Tissues considered high grade have a FIGO score 
of 3 (n=60) or 4 (n=9). The cDNAs of 10 patients were excluded due to a lack of 
grade information. Clinical characteristics of the samples in the array are 
provided in Appendix B. Groups were compared to normal using a two-tailed t-
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test, and significant increase in Rac1b was detected. * indicates significance is 
p<0.05. Serous only, analysis by grade is reported in Figure 31. Data provided 
courtesy of Dr. S.R. Kenney (Department of Pharmaceutical Sciences, University 
of New Mexico)   
 129 
 
 
Figure 31.  Overexpression of Rac1, Rac1b, Cdc42 and RhoA mRNA is 
dependent on ovarian cancer grade. This analysis does not include 
endometrioid tissue.  As per the manufacturer description, patients with 
leiomyoma of myometrium, follicular cysts, abscesses, or secretory 
endometrium, but otherwise healthy ovarian tissue, were considered normal 
(n=11). Data from two normal patients were not included due to Grade 3 
carcinomas of adjacent tissues. Tissues considered low grade have a FIGO 
score of 1 (n=19) or 2 (n=32). Tissues considered high grade have a FIGO 
score of 3 (n=60) or 4 (n=9).  The cDNA of 10 patients was removed because 
they had no grade information. Groups were compared to normal using a two-
tailed t-test, * indicates significance is p<0.05. Data provided courtesy of Dr. S.R. 
Kenney (Department of Pharmaceutical Sciences, University of New Mexico)   
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Study Design and Patient Population  
In previous work, R-ketorolac was identified as an inhibitor of Rac1 and 
Cdc42 at low micromolar concentrations (183, 189). R-ketorolac is inactive 
against the enzyme targets of S-ketorolac, COX-1 and COX-2 (122, 167, 185), 
and the inhibitory concentration (IC50) values for inhibition of Rac1 and Cdc42 by 
S-ketorolac were more than 100-fold greater than R-ketorolac (140). Thus, the 
racemic (R,S) ketorolac possesses two distinct pharmacologic activities and our 
findings identify R-ketorolac as a novel inhibitor of Rac1 and Cdc42. 
In this “Phase 0” feasibility study, ketorolac was administered for its FDA-
approved indication for post-operative pain management. Eligible patients had 
suspected advanced-stage ovarian, fallopian tube or primary peritoneal cancer 
with planned optimal cytoreductive efforts. Secondary eligibility was met if the 
patient had confirmed ovarian cancer, was optimally cytoreduced and had an 
intraperitoneal port placed for planned peritoneal chemotherapy. The patients 
had no active postoperative bleeding, did not require therapeutic anticoagulation 
and had good postoperative organ function. Forty-two patients met primary 
eligibility, and considering secondary eligibility requirements, twenty patient 
samples were collected at surgery. Samples of blood and peritoneal fluids after 
ketorolac administration were obtained from 13 patients. Pathologic analysis of 
the 20 surgical samples confirmed fifteen patients (75%) had stage III or IV 
disease. Histologically, 100% had high-grade carcinoma; one was a 
carcinosarcoma, 16 of 19 were pure serous carcinomas, one was primary 
peritoneal and one fallopian tube primary, and the rest ovarian primary tumors. 
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The average age was 60.8 (range 33-81), race and ethnic distribution was 85% 
Caucasian (29.4% Hispanic), 5% American Indian and 10% Black or African 
American. Ketorolac dosages administered on the basis of clinical indications 
were 15 mg (33% of patients) or 30 mg (77% of patients). As illustrated in Figure 
32A, blood and peritoneal fluid were obtained at T=0, 1 h, 6 h and 24 h after 
administration of the recommended dose of ketorolac.  
Distribution of R- and S-ketorolac in Peritoneal Fluids  
Serum and peritoneal fluid samples were analyzed by HPLC to resolve 
and quantify R- and S-ketorolac enantiomers in order to determine enantiomeric 
ratios and distribution over time (Figure 32B, C). Clinical-grade ketorolac 
tromethamine is a 1:1 mixture of R- and S-enantiomers (Figure 33); however, the 
racemic distribution favors the R-form in both serum and peritoneal fluids at each 
time point in keeping with the established shorter half-life of S-ketorolac in human 
serum based on differences in pharmacokinetic parameters for each enantiomer 
(122, 167, 185). Ketorolac distributes to the peritoneum within 1h after IV 
administration, and ketorolac levels in the peritoneal fluids are nearly equivalent 
to those present in the serum at 6 h and decline dramatically by 24 h in both 
serum and peritoneal fluids. Our results represent the first evidence of ketorolac 
distribution to peritoneal fluids. 
The IC50 values for Rac1 and Cdc42 by R-ketorolac are 0.57 and 1.07 µM, 
respectively, whereas the IC50 values for S-ketorolac for these targets was >100 
µM (183). The concentrations of R- and S-ketorolac in the peritoneal fluids were 
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0.98 µM and 0.32 µM, respectively, 6 h after IV ketorolac administration. Thus, 
R-ketorolac achieved concentrations in the peritoneal fluids at or above the IC50 
values for Rac1 and Cdc42 and is predicted to inhibit these GTPase targets in 
cells obtained from this compartment.  
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Figure 32. Ketorolac distributes to peritoneal fluids and is enriched in the 
R-enantiomer. (A) Ascites samples were obtained at cytoreductive surgery and 
1 to 3 days after surgery patients received a single dose of either 15 mg or 30 mg 
of clinical grade racemic ketorolac. Blood and peritoneal fluid from patients were 
collected before dosing (T=0), and at 1, 6, and 24 h after dosing as depicted by 
the arrows. (B-C) Ketorolac enantiomers (R and S) were measured in blood and 
peritoneal fluids using HPLC. (B) Total ketorolac levels in sera and peritoneal 
fluids. (C) The levels of each ketorolac enantiomer (R or S) at each time point in 
sera and peritoneal fluids were measured. Concentration conversion to 
micromolar in serum and peritoneal fluids is provided in Table 5. Administered 
drug is a 1:1 ratio of R to S (Figure  34), but S-ketorolac is eliminated more 
rapidly than R-ketorolac leading to a ratio favoring the R-enantiomer in both 
serum and peritoneal fluids. The R value for the standard curve used to calculate 
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the ketorolac concentrations was 0.9997 and represented a concentration range 
that spanned established human serum concentrations (0.092 μg/ml to 4.0 μg/ml; 
3.0 μg/ml= 10 μM). Data (panel B, C) data provided courtesy of Dr. S.R. Kenney 
(Department of Pharmaceutical Sciences, University of New Mexico)  
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Analysis of Patient-Derived Cells 
Tumor cell enriched fractions were prepared from ascites samples 
obtained at the time of cytoreductive surgery from ovarian cancer patients and 
post-surgery immediately prior and 1 h, 6 h, and 24 h post IV ketorolac 
administration (Figure 33A). Both Rac1 and Cdc42 were highly activated in 
freshly isolated tumor cells from ascites and the activity level declined within 48 h 
in culture medium (Figure 34A) suggesting that the ovarian tumor environment 
fosters Rac1 and Cdc42 GTPase activation. Post-surgery, we observed a 
statistically significant decrease in Rac1 and Cdc42 activity with time after 
ketorolac administration (Figure 34B, C). In contrast, RhoA activity was 
insensitive to ketorolac (Figure 35), further affirming the selectivity of the drug. R-
ketorolac predominates in the peritoneal fluids at the S-enantiomer is virtually 
undetectable at 24 h (Figure 33C) indicating that the R-enantiomer is bioactive 
and accounts for the observed inhibition of the GTPases in vivo.  
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Figure 33.  Enantiomer analyses of clinical drug. To confirm that this 
apparent shift in racemic ratio was not due to either 1) unequal distribution of the 
racemates in the administered drug or 2) differential extraction of each racemate 
from serum proteins, we conducted control experiments. (A)  Racemic 
distribution of ketorolac enantiomers of the clinically administered drug was 
confirmed by HPLC. (B)  Clinical grade ketorolac incubated with human serum 
(shown) and ascites fluid (not shown, but identical results) at 37°C for 1 h and the 
samples were then processed as for samples obtained from patients. The equal 
distribution of R- and S-ketorolac in the extracted control sample indicates that 
the difference in enantiomer composition in patient samples is not due to 
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differential extraction from serum proteins during sample processing and more 
likely represents a pharmacokinetic parameter such as preferential binding of S-
ketorolac to tissue proteins. Data provided courtesy of Dr. S.R. Kenney 
(Department of Pharmaceutical Sciences, University of New Mexico)   
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Table 5.  Ketorolac enantiomer concentration in serum or peritoneal fluids. 
 
Sample [R] μM [S] μM 
Serum 1h 3.97 1.65 
Serum 6h 1.44 0.33 
Serum 24h 0.40 0.02 
Ascites 1h 0.5 0.33 
Ascites 6h 0.98 0.32 
Ascites 24h 0.27 0.03 
 
Table provided courtesy of Dr. S.R. Kenney (Department of Pharmaceutical 
Sciences, University of New Mexico)   
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Figure 34.  GTPases are activated in patient ascites and inhibited by 
ketorolac administration in vivo. (A) GTPase activity and target inhibition in 
patient-derived cells. GLISA PAK-effector binding was used to individually detect 
activated Rac1-GTP or Cdc42-GTP in tumor cells isolated from ovarian cancer 
patient ascites. Purified GTP-loaded GTPases were used to calculate ng GTP-
bound GTPase in the patient sample. Unpaired two-tailed t tests showed 
samples in culture for 48 h were statistically different from fresh ascites samples 
for both Rac1 and Cdc42 (p=0.0109). The levels of active GTPase declined 
sharply with 48 h in culture, indicating that soluble factors in the ascites serve to 
upregulate Rac1 and Cdc42 GTPase activities. (B-C) Rac1 GTPase target 
inhibition following administration of racemic ketorolac to ovarian cancer patients 
post-surgery. Cells isolated from patient ascites samples post-surgery were 
assayed for active Rac1 orCdc42 using a flow based effector-binding assay. 
Patient diagnoses were all stage III, high grade ovarian serous or papillary 
serous carcinoma, with one mixed serous endometrioid carcinoma and one 
suspected primary peritoneal carcinoma (Pt 20, 24, 35, 39, 43). Fluorescence 
readings were normalized to the 0-h time point drawn immediately before 
ketorolac administration. For Rac1, one way non-parametric ANOVA (p=0.0009) 
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and Bonferroni multiple comparison test, * indicates p<0.05, ** indicates p<0.01: 
0 h versus 6 h (**); 0 h versus 24 h (**); 1 h versus 6 h (*); 1 h versus 24 h (**). 
Differences between 0 h versus 1 h and 6 h versus 24 h were non-significant. For 
Cdc42, one way non-parametric ANOVA (p=0.0250) and Bonferroni multiple 
comparison test, * indicates p<0.05: p<0.05 for 0 h versus 24 h (*) was significant 
and all others were non-significant. RhoA was not responsive to ketorolac (Figure 
35).  
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Figure 35. RhoA activity is insensitive to ketorolac treatment. (A-B) RhoA 
GTPase target inhibition assayed by quantification of active RhoA using a flow 
based Rhotekin effector binding assay. (A) Patient derived tumor cells purified 
from ascites fluids at the time of debulking surgery were treated in vitro for 1 h 
with 10 µM R-ketorolac, S-ketorolac or CID2950007– a Cdc42 selective inhibitor 
(104, 139, 180). Tumor cells incubated with 0.1% DMSO served as a negative 
control. (B) Results of administration of racemic ketorolac to ovarian cancer 
patients post-surgery. Cells isolated from patient ascites samples post-surgery 
were assayed as in (A). Patient diagnoses were stage II-III, high grade ovarian 
serous or papillary serous carcinoma, with one suspected primary peritoneal 
carcinoma (Pt 20, 21, 43). Fluorescence readings were normalized to 0.1% 
DMSO control or the 0 h time point drawn immediately prior to ketorolac 
administration. One way non-parametric ANOVA and Bonferroni multiple 
comparison test showed no statistically significant differences between either the 
ex vivo or the in vivo samples.  
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Retrospective Patient Outcomes Review 
Peri-operative ketorolac was used in 14% of the 123 women in the study. 
Younger women (<50 years) were more likely than older women to receive peri-
operative ketorolac (p<0.05); all other clinical and treatment characteristics were 
similar between the two groups. At 60 months of follow-up, 3 of 17 ketorolac-
treated patients (18%) and 40 of 92 nontreated patients (43%) had died of 
ovarian cancer. Stratified log-rank tests for categorical factors such as age group, 
AJCC stage, completion of chemotherapy as planned, and receipt of neoadjuvant 
chemotherapy as coded in Table 6, showed a consistent ketorolac survival 
benefit in each strata (Appendix C-F). The better survival in women treated with 
ketorolac consistently found in the stratified analysis was also evident in the 
proportional hazards analysis when we adjusted for age at diagnosis, AJCC 
stage, completion of chemotherapy as planned, and receipt of neoadjuvant 
chemotherapy. The adjusted HR for ovarian cancer-specific mortality associated 
with perioperative ketorolac (yes vs. no) was 0.30 [95% confidence interval (CI), 
0.11-0.88, Table 6]. On the basis of the proportional hazards model, an example 
survival plot is shown in Figure 36 for women who had AJCC stage III cancer, 
were 50 to 60 years at diagnosis, did not receive neoadjuvant therapy, and 
completed post-surgery chemotherapy as planned. Other survival plots are 
shown in Appendix C-F, and although these plots highlight the results for women 
who completed their post-surgery chemotherapy as planned, all combinations of 
women defined by stage of disease, age at diagnosis, neoadjuvant therapy, and 
post-surgery chemotherapy showed a consistently better survival with ketorolac 
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versus without. These preliminary findings suggest that perioperative ketorolac 
reduces ovarian cancer-specific mortality.  
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Table 6.  Hazard ratios for ovarian cancer specific mortality for each 
characteristic adjusted for the other characteristics in the table.  
 
Data provided courtesy by Dr. L. Cook (Division of Epidemiology, Biostatistics 
and Preventive Medicine, Department of Internal Medicine, University of New 
Mexico School of Medicine). 
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Figure 36.  Retrospective survival analyses among ovarian cancer patients 
with and without peri-operative ketorolac. Cox proportional hazards 
regression was used to estimate ovarian cancer specific survival probabilities for 
women who did (dashed line,17 women) and did not (solid line, 92 women) 
receive ketorolac among ovarian cancer cases with AJCC Stage III cancer, 50-60 
years of age at diagnosis, no neo-adjuvant chemotherapy and completed 
chemotherapy as planned (overall adjusted Hazard Ratio = 0.30, 95%CI = 0.11 – 
0.88, likelihood ratio test p-value = 0.013). Data provided courtesy by Dr. L. Cook 
(Division of Epidemiology, Biostatistics and Preventive Medicine, Department of 
Internal Medicine, University of New Mexico School of Medicine). 
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Conclusion and Discussion 
In many human cancers, aberrant Rho-family GTPase activity or 
downstream signaling pathways are associated with increased aggressiveness 
and poor patient prognosis (54, 153, 173, 175, 176, 178). The specific 
mechanisms by which Rho-family GTPases modulate tumor development and 
progression remain under investigation (54, 68, 107, 153, 175, 176); however, 
experimental evidence places Rac1 and Cdc42 within the metastatic cascade. 
Little is known regarding Rac1 and Cdc42 expression in ovarian cancer. We 
demonstrated elevated expression of Rac1 and Cdc42 in human ovarian cancer 
specimens and high activity of these GTPases in freshly isolated tumor cells from 
ascites obtained at surgery (Figure 30 and 34). In a recent study, high Rac1 
protein expression in ovarian cancer was associated with early recurrence and 
poor prognosis (77). Furthermore, partial silencing of Rac1 by shRNA decreased 
tumor cell proliferation, migration and invasion in culture, and decreased growth 
of subcutaneous ovarian cancer xenografts in vivo (77). We find that R-ketorolac 
inhibits adhesion and invasion of primary human ovarian tumor cells from patient 
ascites (183) thereby indicating that pharmacologic inhibition of Rac1 and Cdc42 
also blocks these tumor-relevant functions. These observations in conjunction 
with inhibition of ovarian tumor cell migration by a Cdc42-specific inhibitor (180) 
indicate the potential value of targeting Rac1 and Cdc42 in ovarian cancer. 
The present chapter presents evidence that Rac1 and Cdc42 inhibition 
can be achieved in ovarian cancer patients following administration of racemic 
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ketorolac (Toradol®). Ketorolac is a 1:1 racemic mix of the R- and S-enantiomers. 
The S-form inhibits COX enzymes which confers the drug’s anti-inflammatory 
activities. The COX inhibitory action of S-ketorolac supports its indication for 
postoperative pain management, but also limits its long term use due to COX-
related toxicity (122, 167, 185). R-ketorolac has little activity against COX (122, 
167, 185) and therefore is not functional as an NSAID, but is bioactive and 
inhibits Rac1 and Cdc42 (183). Importantly, the levels of R-ketorolac within the 
peritoneal fluids were sufficient to inhibit Rac1 and Cdc42 activity in cells 
obtained from the peritoneal cavity following ketorolac administration. The 
innovative Phase 0 clinical trial design enabled real-time sampling of fluids and 
cells from the peritoneal cavity. Direct demonstration of the difference in racemic 
distribution of ketorolac enantiomers illustrates the value of a study design that 
allows direct testing of drug and cell activities within peritoneal fluids rather than 
extrapolation from serum drug levels. 
Furthermore, the peritoneal bioactivity of ketorolac is shown to have 
benefit for ovarian cancer patient outcomes. Perioperative use of ketorolac was 
found to reduce ovarian cancer specific mortality (Figure 36). There is 
precedence in the literature that ketorolac usage in the perioperative period is 
associated with improved cancer outcomes. The first observation was made for 
breast cancer patients in 2010 (169). In this study, ketorolac use was associated 
with a decreased risk of breast cancer relapse (HR=0.37, 95%CI=0.0-0.79). 
Follow-up papers noted that this relapse reduction was most pronounced in the 
first 24 months post-surgery (53, 184). No change in breast cancer recurrence 
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was noted in patients who received sufentanil, clonidine, ketamine, or other 
intraoperative analgesics. Lung cancer patients receiving ketorolac displayed 
improved overall survival as well (190). The authors hypothesize that the benefit 
is due to the anti-inflammatory actions of ketorolac, particularly on the 
extravasation of circulating tumor cells in the transient inflammatory environment 
stimulated by surgery (172). Ketorolac appears to have more pronounced 
positive outcomes than other NSAIDs (172), and this may be based on the 
combined impact of anti-inflammatory activity by the S-enantiomer and R-
enantiomer effects on Rac1 and Cdc42 leading to decreased adhesion and 
implantation of circulating or residual tumor cells. Ketorolac is not cytotoxic to 
ovarian tumor cells (183), but predicted decreases in establishment or further 
development of micrometastases due to Rac1 and Cdc42 inhibition would be 
expected to improve response to subsequent chemotherapy, which cannot be 
initiated until patients have recovered from cytoreductive surgery. Therefore, 
administration of ketorolac during a key therapeutic window may offer a 
particularly efficacious benefit against later relapse. 
Collectively, the findings support the potential repositioning of ketorolac as 
an addition to current ovarian cancer therapy. The work demonstrates that the R-
enantiomer of ketorolac acts as a first-in-class drug for inhibition of the cancer-
relevant targets Rac1 and Cdc42 (182, 183) and provides the first evidence that 
these therapeutic targets can be inhibited in humans using an approved drug. 
There is precedence for pharmacologic activities dictated by R-enantiomers of 
specific NSAIDs against novel (non-COX) targets (191-193). For example, R-
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etodolac and its analogs SDX-301 and SDX-308 display antitumor activity in 
chronic lymphocytic leukemia and activity against multiple myeloma in cell and 
animal models (192, 194-197). R-etodolac also significantly suppressed tumors 
in a colitis-related mouse model colon cancer (191) and retarded tumor 
development and metastasis in a transgenic mouse model of prostate cancer 
(193). These examples and others demonstrate that R-enantiomers of NSAIDs 
can possess unanticipated anticancer activities based on interactions with non-
COX targets. Further evidence that targeting Rac1 may provide therapeutic 
benefit in ovarian cancer was recently reported (198). Zoledronic acid is a 
nitrogen containing bisphosphonate that inhibits prenylation of small GTPases. 
Administration of this drug decreased growth of ovarian cancer peritoneal 
xenografts through inhibition of angiogenesis driven by a Rac1-mediated 
pathway (198). Collectively, the results suggest that racemic ketorolac may 
provide a survival benefit to ovarian cancer patients through inhibition of COX 
enzymes by the S-enantiomer and inhibition of the small GTPases Rac1 and 
Cdc42 by the R-enantiomer. Additional studies to determine whether clinical 
benefit can be observed in ovarian cancer patients through perioperative 
administration of ketorolac in a placebo-controlled clinical trial are in process.  
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CHAPTER 5 
FUTURE PERSPECTIVES 
In this thesis work, R-ketorolac is established as a potential anti-tumor drug 
with previously unrecognized pharmacological property. R-ketorolac is identified 
as an allosteric inhibitor of Cdc42 and Rac1 using an in vitro nucleotide binding 
assay. To validate the anti-tumor impact of R-ketorolac, a human patient 
immortalized ovarian cancer cell line (SKOV3ip) and primary ascites-derived 
ovarian cancer cells were used to demonstrate that R-ketorolac inhibits the 
activation of Cdc42 and Rac1 and their downstream PAK signaling axis. As a 
consequence of the inhibition there is a reduction in ovarian cancer cell adhesion, 
migration and invasion. In a phase 0 clinical trial, R-ketorolac is found to achieve 
an effective concentration and persistence in peritoneal fluids for 24 hours. Rac1 
and Cdc42 activities in cells retrieved from the peritoneal compartment of post-
surgical ovarian cancer patients were substantially reduced in a time-dependent 
manner following a single IV ketorolac dose for post-operative pain management. 
A medical record review to compare the ovarian cancer-specific survival of 
ovarian cancer patients who did or did not receive ketorolac revealed an 
improved survival with perioperative use of ketorolac. We speculate that 
ketorolac benefits ovarian cancer patient outcomes through targeted inhibition of 
Cdc42 and Rac1 GTPases, which in turn decreases adhesion and implantation 
of circulating or residual tumor cells and/or tumor stem cells. 
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 Docking studies predict R-ketorolac inhibits Cdc42 and Rac1 GTPase 
activity by excluding magnesium, which is induced by the carboxyl moiety at the 
chiral center. Follow-on SAR studies support the docking in that trifluoromethyl 
and 2-thiophene alter ketorolac activity possibly through impact on the carboxyl 
group at the chiral center. Derivatives modified by trifluoromethyl on the phenyl 
ring or substitution of the phenyl ring with the heterocyclic, aromatic 3-thiophene  
selectively switched the activity of ketorolac from inhibition to activation on 
GTPase activity with increased potencies, indicating that an aromatic ring may 
increase lipophilic binding to the GTPases, while still accommodating bound 
nucleotide. To further elucidate the mechanism, SAR analysis will need to be 
extended by making additional variants of these promising parent compounds.  
The 3-thiophene is of particular interest because of a potential for increased 
Rac1 selectivity. The modified analogs with enhanced activity would provide 
guidance to develop more effective inhibitors. On the other hand, to further verify 
the magnesium exclusion mechanism of R-ketorolac inhibition against Cdc42 
and Rac1, nucleotide binding assays should be performed on GTPase mutants 
targeting putative amino acid contact points with the docked compound. For 
example, the methyl group of alanine 59 within Cdc42 or equivalent in Rac1 has 
been shown to impinge upon magnesium binding within the GEF-GTPase 
complexes. Introduction of A59G point mutant, which significantly cripples GEF 
binding and exchange, should be constructed as one way to validate if 
magnesium exclusion is essential for R-ketorolac activity (199, 200).   
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Malignant ascites is the accumulation of peritoneal fluid, and is frequently 
found in high-grade ovarian cancer patients. Ascites is composed of soluble 
factors such as growth factors, cytokines, and cellular components such as tumor 
cells, associated stromal cells (mesothelial and fibroblast cells) and inflammatory 
cells, which provide a pro-inflammatory and tumor-promoting microenvironment 
(21, 23, 201). Tumor cells in ovarian cancer ascites trigger disease recurrence 
(202). In the current study, ascites-derived tumor cells are used for the cell-based 
studies.  Compared to immortalized tumor cells, the use of ascites-derived tumor 
cells represents a more experimentally accurate model to evaluate the impact of 
ketorolac on ovarian tumor growth and metastasis (18, 21, 23, 201-204). For the 
initial analyses, the cell adhesion, migration and invasion assays were performed 
in a 2-D environment, which lack the architectural and cellular complexity of 
tumors in vivo. To mimic the in vivo human microenvironment, further study will 
require testing the impact of ketorolac on ovarian tumor adhesion and invasion in 
a three-dimensional (3-D) organotypic system or using omental explants (205); 
the omentum is a preferred seeding site for ovarian tumor metastases in vivo 
(206). In the 3-D organotypic model, primary human ovarian tumor cells or 
immortalized tumor cell lines are cultured with primary human mesothelial cells 
isolated from patient omentum, primary human fibroblast and patient-derived 
ECM which mimic the superficial layer of the peritoneum (204, 207). This ex vivo 
model or omental explants could help establish structural and functional 
environment of the ovarian tumor tissue for tumor metastasis including adhesion, 
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migration and invasion, which will provide a more accurate system for drug 
screening (204, 208).  
The retrospective study shows racemic ketorolac has pronounced benefits 
on patient survival outcomes. The findings that R-ketorolac targets Rac1 and 
Cdc42, but not RhoA and reduces cell adhesion, migration and invasion of tumor 
cells suggests that the drug may reduce relapse by making the remaining tumor 
cells more vulnerable to chemotherapy post-debulking surgery.  Accumulating 
evidence show that cancer stem cells are enriched after first-line chemotherapy 
for advanced stage ovarian cancer patients, leading to tumor relapse with 
chemoresistance. The cancer stem cell model could also explain the 
heterogeneity of phenotypic and functional features in epithelial ovarian cancer, 
contributing to the poor diagnosis and prognosis (209, 210). Rac1 
overexpression is also implicated in quiescence, stemness and cancer cell 
adhesion to the bone marrow niche (211-213). Therefore, it is also conceivable 
that through an impact on cancer stem cell Rac1 activity R-ketorolac could 
increase cell cycling and reduce sequestration of tumor cells or cancer stem cells 
in a protected niche. Both mechanisms would increase chemotherapy sensitivity 
and account for the observed improved survival. Thus, targeting of cancer stem 
cells by ketorolac to suppress proliferation and metastasis would be another 
explanation for the observed benefits.  Further studies of niche adhesion and 
quiescence in preclinical animal models are needed to evaluate ovarian tumor 
cell homing to the bone marrow or peritoneal niches. Immortalized ovarian cell 
lines have been reported to be heterogeneous with highest fractions of stem-like 
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cells detected in the most aggressive lines (214). NSAIDs have been reported to 
suppress stem cells proliferation, metastasis and differentiation through a COX-
dependent (e.g.  PGE2 – NF - κB) or a COX - independent manner (e.g. cell cycle 
regulators) (215-217). Future work will require investigation of the impact of 
ketorolac on the proliferation, differentiation and metastasis of ovarian cancer 
stem cells by using patient-derived ovarian tumor stem cells (e.g. CD133 positive 
selection) (218, 219). Identifying molecular targets of ketorolac in cancer stem 
cells and developing ketorolac as an adjuvant anti-tumor therapy could 
potentially increase tumor sensitivity to chemotherapy, reduce recurrence, and 
improve ovarian cancer patient outcomes (209, 210).  
There are other possibilities for the reduced mortality observed in 
retrospective analyses of patients receiving post-operative ketorolac as 
compared to patients who had surgery only or received opiod pain relievers. For 
example, surgery induced inflammation is known to increase stimulation and 
proliferation of residual tumor cells.  S-ketorolac present in the racemic clinical 
drug is a powerful anti-inflammatory and has been suggested to provide benefit 
in breast cancer patients on account of this anti-inflammatory activity (53, 220). 
However, a purely anti-inflammatory role mediated by COX inhibition by S-
ketorolac has been challenged (221). It is also inconsistent with the specificity of 
ketorolac in reducing tumor relapse in ovarian cancer as demonstrated here, and 
also reported while the studies were in progress in breast, kidney and other 
cancers (190, 220). Addressing this question will require further testing in 
preclinical animal models, e.g. surgery +/- drug administration +/- tumor cells.  
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To more directly compare if the inhibition of GTPase activity is purely drug-
mediated or due to other changes in the post-operative peritoneal cavity, a 
prospective clinical trial is needed in which patients will be given placebo after 
surgery and their primary tumor cells will be processed for GTPase activity 
assays and related measures of GTPase activation. A small placebo trial will 
further confirm that the observed inhibition of GTPase activity is dependent on 
ketorolac administration.  Through longer term tracking of patients in the trial, 
GTPase inhibition can be evaluated as a surrogate for time to relapse, 
progression free survival, and overall survival. Only through continued systematic 
study can the therapeutic benefits of patient outcomes be specifically attributed 
to ketorolac administered during perioperative period.  
Overall, future studies will focus on 1) identifying critical determinants for 
Rho GTPase inhibition and developing more effective and selective Cdc42/Rac1 
inhibitors; 2) establishing 3-D organotypic models for testing GTPase inhibitors 
alone or in combination; 3) investigating the impact of ketorolac on stem cells in 
ovarian cancer and other epithelial cancers; 4) conducting a placebo-controlled 
clinical trial to confirm the clinical benefit of ketorolac. These studies will offer a 
rapid translational and clinical study to repurpose FDA-approved drug-ketorolac 
as an anti-tumor drug for ovarian cancer therapy.   
 156 
 
APPENDICES 
 
Appendix A.  Time lapse imaging of HPY (490) labeled fluorescent 
compound RS-II-79 penetration into MCA. In the experiment, 2000 
multicellular aggregates (SKOV3ip cells) were incubated with 10 µM RS-II-79. 
The images were captured at 9, 22, 40, 42, 54 and 66 min by Zeiss Axiovert 200 
M inverted confocal microscope. Images provided courtesy of Dr. M. Steinkamp 
(Department of Pathology, University of New Mexico). 
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Appendix B. Patient Characteristics for IHC Microarrays OV1005 and 
OV8010 
 
Age# 46.6 +/- 13.7 (std. dev) 
Stage I#  12 
 A 5 
 B 5 
 C 4 
Stage II#  21 
 A 13 
 B 6 
 C 3 
Stage III#  1 
 C 31 
Stage IV#  11 
Stage undetermined#  51 
Normal stroma  20 
Benign/borderline   25 
Grade - Low* (1#)  13 
Grade - Intermediate* (1-2, 
2#)  7 
Grade - High* (2, 2-3, 3#)  98 
*Diagnoses by board certified pathologist with gynecologic pathology 
specialization were as follows:  Clear cell carcinoma (4); endometrioid  
carcinoma (13); endometrioid neoplasm (5); mucinous carcinoma (4); 
mucinous neoplasm (9); mucinous cystadenoma (5); normal stroma 
only-no epithelia (20); papillary serous carcinoma (78); serous 
neoplasm (5); serous cystadenoma (4); undifferentiated carcinoma 
(16). There was 77% agreement with #BioMax specification sheet, 
differences were confined to ID of rarer subtypes (endometrioid, clear 
cell, mucinous, transitional and serous). Samples included in analysis: 
163 of 180 total (9% were excluded due to poor staining at edge of 
slide or no neoplasm in the section).  
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Appendix C. Patient Characteristics for cDNA Microarray 
Age 57.26 -/+ 14.85 (st. dev) 
Stage I A 20 
 B 8 
 C 10 
Stage II A 4 
 B 9 
 C 4 
Stage III A 15 
 B 17 
 C 26 
Stage IV A 10 
Grade Not Reported   10 
Grade I  9 
Grade II  32 
Grade III  60 
Grade IV  9 
Diagnoses were as follows:  Carcinoma of Ovary (2); Carcinoma of ovary, endometrioid 
(6); Carcinoma of ovary, papillary serous (8);  
Carcinoma of ovary, clear cell (1); Adenocarcinoma of ovary, endometrioid (23); 
Adenocarcinoma of ovary, papillary serous (32); Adenocarcinoma of ovary, serous (28); 
Adenocarcinoma of ovary, metastatic (2); Adenocarcinoma of ovary, mucinous (4); 
Adenocarcinoma of ovary, clear cell (5); Tumor of ovary, borderline (2); Tumor of ovary, 
papillary serous, borderline (2); Tumor of ovary, serous, borderline (5) 
 These microarray plates consisted of 19 normal, 9 Grade I, 32 Grade II, 60 Grade III, 9 
Grade IV, and 10 grade not reported patients. Patients with grade not reported were not 
included in grade analysis. 
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Appendix D. Survival estimates based on Cox-regression for Stage I (AJCC) 
with completion of chemotherapy. Cox proportional hazards regression was 
used to estimate ovarian cancer specific survival probabilities for women who did 
(dashed line) and did not (solid line) receive ketorolac among ovarian cancer 
cases with AJCC Stage I cancer, sorted by age group and -/+ neoadjuvant 
chemotherapy. Data provided courtesy of Dr. L. Cook (Division of Epidemiology, 
Biostatistics and Preventive Medicine, Department of Internal Medicine, 
University of New Mexico School of Medicine). 
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Appendix E.  Survival estimates based on Cox-regression for Stage II 
(AJCC) with completion of chemotherapy. Cox proportional hazards 
regression was used to estimate ovarian cancer specific survival probabilities for 
women who did (dashed line) and did not (solid line) receive ketorolac among 
ovarian cancer cases with AJCC Stage II cancer, sorted by age group and -/+ 
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of 
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal 
Medicine, University of New Mexico School of Medicine). 
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Appendix F. Survival estimates based on Cox-regression for Stage III 
(AJCC) with completion of chemotherapy. Cox proportional hazards 
regression was used to estimate ovarian cancer specific survival probabilities for 
women who did (dashed line) and did not (solid line) receive ketorolac among 
ovarian cancer cases with AJCC Stage III cancer, sorted by age group and -/+ 
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of 
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal 
Medicine, University of New Mexico School of Medicine). 
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Appendix G. Survival estimates based on Cox-regression for Stage IV 
(AJCC) with completion of chemotherapy. Cox proportional hazards 
regression was used to estimate ovarian cancer specific survival probabilities for 
women who did (dashed line) and did not (solid line) receive ketorolac among 
ovarian cancer cases with AJCC Stage IV cancer, sorted by age group and -/+ 
neoadjuvant chemotherapy. Data provided courtesy of Dr. L. Cook (Division of 
Epidemiology, Biostatistics and Preventive Medicine, Department of Internal 
Medicine, University of New Mexico School of Medicine). 
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